

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iscon Bopal Road,
Ambli, Ahmedabad Gujarat 380058

compliance@arveelabs.com CIN : L24231GJ2012PLC068778

www.arveelabs.com, Tel : 91- 2717-430479

=====

NOTICE

Notice is hereby given that the 9th Annual General Meeting of the members of Arvee Laboratories (India) Limited will be held at on Tuesday, 29th September, 2020 at 11:00 a.m. through Video Conferencing ("VC")/ Other Audio- Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited Balance Sheet as at 31st March, 2020 and Statement of Profit & Loss Account and Cash Flow Statement for the year ended on 31st March, 2020 and the Reports of the Board of Directors and Auditors thereon.
2. To appoint Mr. Shalin Bharatbhai Chokshi (having Director Identification Number : 00191903) a Director of the Company who retires by rotation and being eligible offers himself for reappointment.

SPECIAL BUSINESS

3. To consider and if thought fit to pass with or without modification the following resolution as an Ordinary Resolution for appointment of Mr. Paragbhai Manubhai Shah as an Independent Director :

“RESOLVED THAT, pursuant to the provision of Section 149, 150 and 152 and other applicable provision, if any, of the Companies Act, 2013 and rules made there under read with Schedule IV of the Companies Act, Mr. Paragbhai Manubhai Shah (DIN : 08773974) who was appointed as an Additional Director with effect from 27th June, 2020 under Section 161 of the Companies Act 2013 be and is hereby appointed as Independent Director of the Company to hold office for a term upto five consecutive years commencing from 27th June, 2020 and shall not be liable to retire by rotation”

RESOLVED FURTHER THAT pursuant to Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, approval of the Members be and is hereby accorded to the continuation of directorship of Paragbhai Manubhai Shah (DIN : 08773974) after he attains the age of 75 years, as an Independent Director of the Company

To consider and if thought fit to pass with or without modification the following resolution as an Ordinary Resolution for Increase in Authorised Share Capital and consequent alteration in the Memorandum of Association

4. :

“RESOLVED THAT and provisions of Sections 61 and 13 and other applicable provisions, if any, of the Companies Act, 2013, read with (Share Capital and Debentures) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Articles of Association of the Company, the authorized share capital of the Company be increased from Rs. 6,00,00,000 (Rupees Six Crores) divided into 60,00,000 (Sixty Lacs) equity shares of the face value of Rs. 10 (Rupees Ten) each to Rs. 11,25,00,000 (Rupees Eleven Crores Twenty Five Lacs) divided into 1,12,50,000 (One Crore Twelve Lacs Fifty Thousand Only) equity shares of the face value of Rs. 10 (Rupees Ten) each by creation of additional capital of Rs. 5,25,00,000 (Rupees Five Crores Twenty Five Lacs Only) divided into 52,50,000 (Fifty Two lacs Fifty Thousand Only) equity shares of the face value of Rs. 10 (Rupees Ten) each ranking pari-passu with the existing equity shares of the Company.”

“Resolved further that, the Existing Clause V of the Memorandum of Association of the Company be and is hereby altered as :

V. The Authorised Share Capital of the Company is Rupees 11,25,00,000 (Rupees Eleven Crores Twenty Five Lacs) divided into 1,12,50,000 (One Crore Twelve Lacs Fifty Thousand Only) equity shares of the face value of Rs. 10 (Rupees Ten Only) each

“FURTHER RESOLVED THAT the Chairman and Managing Director of the Company or any one of the Directors of the Company or the Company Secretary of the Company be and are hereby authorised to do all such things, acts, deeds and matters as may be considered necessary, usual, proper or expedient to give effect to the above resolution, including but not limited to incorporation of amendment / suggestion / observation made by the Ministry of Corporate Affairs, to the extent applicable, without being required to seek any further consent or approval of the Members of the Company or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.”

5. To consider and if thought fit to pass with or without modification the following resolution as an Special Resolution for issue of bonus shares by way of capitalization of reserves :

“RESOLVED THAT pursuant to Section 63 and other applicable provisions of the Companies Act, 2013, read with Rule 14 of the Companies (Share Capital & Debentures) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), the relevant provisions of the Memorandum and Articles of Association of the Company, subject to regulations and guidelines for bonus shares issued by Securities and Exchange Board of India (as amended from time to time), as applicable and such permission, approval and sanctions as may be required in this connection, the consent of the members be and is hereby

accorded to the Board of Directors (hereinafter referred to as "Board" which term shall be deemed to include any Committee which the Board constitutes / has constituted to exercise its powers including powers conferred by this resolution) for capitalization of amount of Rs, 5,51,00,000 (Rupees Five Crores Fifty One Lacs Only) out of the securities premium account or such other reserves as are permitted to be utilized for this purpose, as per audited financial statements for the financial year ended on March 31, 2020, for the purpose of issuance of bonus shares of (Rupees Ten only) each, credited as fully paid-up shares to the holders of the existing equity shares of the Company, whose names appear in the Register of Members / List of Beneficial Owners, as received from the National Securities Depository Limited and Central Depository Services (India) Limited, on such date (record date) as may be fixed in this regard by the Board which shall also include any committee thereof, in the proportion of 1 (one) fully paid up bonus equity share of each for 1 (one) fully paid up equity share of each held by the members and that the bonus shares so allotted shall, for all purpose, be treated as an increase in paid-up share capital of the Company held by each member and not as an income

"RESOLVED FURTHER THAT bonus shares so issued and allotted shall rank pari passu in all respect including dividend with existing fully paid-up equity shares of the Company and that such shares shall always be subject to the terms and conditions contained in the Memorandum and Articles of Association of the Company."

"RESOLVED FURTHER THAT, shares held in dematerialized form, the Bonus shares will be credited to the respective demat account of the holders.

"RESOLVED FURTHER THAT, in case of fractional shares, if any, arising out of the issue and allotment of the bonus equity shares, the Board be and is hereby authorized to make suitable arrangements to deal with such fractions for the benefit of the eligible Members, including but not limited to, allotting the total number of new equity shares representing such fractions to a person(s) to be appointed by the Board of Directors who would hold them in trust for such Members and shall, as soon as possible, sell such equity shares at the prevailing market rate and the net sale proceeds of such equity shares, after adjusting the cost and the expenses in respect thereof, be distributed among such Members who are entitled to such fractions in the proportion of their respective fractional entitlements.

"RESOLVED FURTHER THAT the issue and allotment of bonus shares to NonResident, Person of Indian Origin and other foreign investors of the Company shall be subject to approval of Reserve Bank of India under the provisions of Foreign Exchange Management Act, 1999 and rules and regulations made thereunder and / or any other regulatory authority(ies), as may be required."

"RESOLVED FURTHER THAT the Board be and is hereby authorized to take all other steps as may be necessary to give effect to the aforesaid resolution and determine all other terms and conditions of the issue of bonus shares as the Board may in its absolute discretion deem fit."

"RESOLVED FURTHER THAT for the purpose of giving effect of bonus equity shares, the Board and / or any designated officer/s of the Company be and are hereby severally authorised to do all such acts, deeds and things as per their discretion and deem necessary for said purpose including but not limited to filing

of forms / documents with Ministry of Corporate Affairs, Securities and Exchange Board of India, Reserve Bank of India, Stock Exchanges and Depositories.”

6. To consider and if thought fit to pass with or without modification the following resolution as an Ordinary Resolution for the cost auditor:

‘Resolved That pursuant to Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, M/s. P. H. Desai & Co. (Firm Membership number 100377),, Cost Accountants, appointed as Cost Auditors by the Board of Directors to audit the cost records of the Company for the fiscal year 2020-21, be paid a remuneration of Rs. 25,000/- per annum plus applicable taxes and out-of-pocket expenses that may be incurred..

Resolved Further That the Board of Directors of the Company be and is hereby authorised to perform all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution’

7. To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution for grant of approval of related party transactions :

“RESOLVED THAT pursuant to the provisions of section 188 and other applicable provisions of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any amendment, modification, variation or re-enactment thereof for the time being in force), consent of the Members of the Company be and is hereby accorded to the Board of Directors (hereinafter referred to as “the Board” which term shall be deemed to include any Committee of the Board), to enter into contracts/ arrangements/ agreements/ transactions (including any modifications, alterations or amendments thereto) in the ordinary course of business and on arm’s length basis with related parties within the meaning of the Act and Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, as more particularly enumerated in the explanatory statement annexed to the Notice on such terms and conditions as may be agreed between the Company and its related party.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do or cause to be done all such acts, deeds, things, settle any queries, doubt that may arise with regard to any transactions with the related party, make such changes to the terms and conditions as may be considered necessary or desirable in order to give effects to this Resolution in the best interest of the Company.”

Notes:

1. An Explanatory Statement pursuant to Section 102 (1) of the Companies Act, 2013 (hereinafter referred to as the “Act”), in respect of businesses to be transacted at the Annual General Meeting (hereinafter referred to as “AGM”), as set out under Item

No(s). 3 to 7 above and the relevant details of the Directors as mentioned under Item No (s). 2 to 3 above as required by Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 (hereinafter referred to as "Listing Regulations") and as required under Secretarial Standards – 2 on General Meetings issued by the Institute of Company Secretaries of India, is annexed thereto.

2. The Board of Directors have considered and decided to include the Item nos. 4 to 7 given above as Special Business in the forthcoming AGM, as they are unavoidable in nature.
3. **In view** of the massive outbreak of the COVID-19 pandemic, social distancing is a norm to be followed and pursuant to the Circular No. 14/2020 dated April 08, 2020, Circular No.17/2020 dated April 13, 2020 issued by the Ministry of Corporate Affairs followed by Circular No. 20/2020 dated May 05, 2020, physical attendance of the Members to the AGM venue is not required and annual general meeting (AGM) be held through video conferencing (VC) or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM.
4. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate thereat and cast their votes through e-voting.
5. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
6. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as venue voting on the date of the AGM will be provided by NSDL.
7. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company

at www.arveelabs.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. National Stock Exchange of India Limited at www.nseindia.com and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

8. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 08, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
9. Members holding Shares in Electronic mode are requested to register/ update their e-mail address with their respective Depository Participants "DPs" for receiving all communications from the company electronically.
10. The Company has engaged the services of Accurate Securities & Registry Private Limited, Registrar and Transfer Agent as the authorized agency for conducting of e-AGM and providing e-voting facilities.
11. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
12. All documents referred to in the notice and the explanatory statement requiring the approval of the Members at the meeting and other statutory registers shall be available for inspection by the Members at the Registered Office of the Company during office hours on all working days between 10.00 a.m. to 5.00 p.m. from the date of hereof up to the date of the Annual General Meeting.
13. The Register of Members and Share Transfer Books will remain close from Thursday, .day, 24th September, 2020 to Wednesday, 30th September, 2020 (both days inclusive) for the purpose of annual closing and Annual General Meeting.
14. The Members of the company holding Shares as on Friday,, 21st August, 2020 (Cut-off date for entitlement of Annual Report), shall be eligible for receiving the Annual Report 2019-20 along with the notice of the Annual General Meeting, by electronic mode to all the members whose email addresses are registered with the Depository Participant(s).
15. Members can avail the nomination facility by filing Form No. SH-13, as prescribed under Section 72 of the Companies Act, 2013 and rule 19 (1) of the Companies (Share Capital and debentures) Rules 2014 with the Company. Blank forms will be supplied on request.
16. Members who hold shares in dematerialized mode are requested to intimate any changes pertaining with their bank account details, ECS mandates, nominations, change of address/name etc. to their Depository Participant. Changes intimated to the Depository Participant will then be automatically reflected in the Company's records

which will help the Company and its Registrar & Share Transfer Agent to provide efficient and better service to the members.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-

The remote e-voting period begins on Saturday, 26th September, 2020 at 09:00A.M. and ends on Monday, 28th September, , 2020 at 05_:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Log-in to NSDL e-Voting system at <https://www.evoting.nsdl.com/>

Step 2: Cast your vote electronically on NSDL e-Voting system. Further note EVEN number for voting is 113863

Details on Step 1 is mentioned below:

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholders’ section.
3. A new screen will open. You will have to enter your User ID, your Password and a Verification Code as shown on the screen.
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID

	For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 113863 then user ID is 113863001***

5. Your password details are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) **If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

- a) Click on "[Forgot User Details/Password?](#)" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
- b) [Physical User Reset Password?](#) (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
- c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address.

d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Details on Step 2 is given below:

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see the Home page of e-Voting. Click on e-Voting. Then, click on Active Voting Cycles.
2. After click on Active Voting Cycles, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle is in active status.
3. Select “EVEN” of company for which you wish to cast your vote.
4. Now you are ready for e-Voting as the Voting page opens.
5. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
6. Upon confirmation, the message “Vote cast successfully” will be displayed.
7. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
8. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

- 1 Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to admin@csjalan.com with a copy marked to evoting@nsdl.co.in.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “[Forgot User Details/Password?](#)” or “[Physical User Reset Password?](#)” option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990 or send a request to (Name of NSDL Official) at evoting@nsdl.co.in

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice :

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to compliance@arveelabs.com.

In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to compliance@arveelabs.com.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same at <https://www.evoting.nsdl.com> under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVEN of Company will be displayed. Please note that the members who

do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush. Further members can also use the OTP based login for logging into the e-Voting system of NSDL.

2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at (company email id). The same will be replied by the company suitably.

FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED

Place: Ahmedabad
Dated: 24th August, 2020

Sd/-

DIRECTOR
Shalin Sudhakarbhai Patel

ANNEXURES TO THE NOTICE

ANNEXURE: A

Details of the Director retiring by rotation and seeking Re-appointment at the Annual General meeting pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and Secretarial Standard: 2 (SS:2) issued by ICSI and approved by the Central Government.

Name of the Director	Shalin Bharatbhai Chokshi
Father's Name	Bharatbhai Chokshi
Date of Birth	16/10/1984
Qualification	He is a graduate in commerce and holds a degree in Masters of Professional Accounting, Monash University, Australia.
Date of Joining the Board of Director of the Company	27/01/2012
Number of Shares held in the Company	669000
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Nil
Other Chairmanship / Membership of Committees of Board of other Companies	Nil
Specific Functional Area	He has been pivotal in bringing new international raw material suppliers to the Company which has proved to be highly cost beneficial to the company. At the same time he has identified key consumers for Company's products in the International market. He closely monitors Company affairs and its functions
Relationship with Directors / inter-se KMP	Nil as on 31 st March, 2020

Experience	Mr. Shalin Bharat Chokshi, aged 35 Years, is the Promoter and Whole Time Director of our Company. He is a graduate in commerce and holds a degree in Masters of Professional Accounting, Monash University, Australia. He has 10 years of experience in sales and international business. He has worked with Companies like B Chokshi Chem Private Limited, where he was responsible for developing new clients as well as suppliers. He has been instrumental in identifying new suppliers to strategically improve the Company supply chain.
Terms and Conditions of appointment	As per the agreement entered with effect from 4 th December, 2017. He is appointed on annual salary of Rs. 12,00,000 with effect from 4 th December, 2017 with the Power of the Board of Directors to increase his remuneration upto 25% per annum.
Remuneration sought to be paid and last drawn	Rs. 12.00 lacs plus perquisites.
Number of meeting of Board of Directors attended during the year	6

FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED

Place: Ahmedabad
Dated: 24th August, 2020

-

Sd/-

DIRECTOR
Shalin Sudhakarbhair Patel

Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 in respect of item No. 3 to 7 is as under :

Item No. 3

The Board of Directors of the Company at its meeting held on June 27, 2020, appointed Mr. Parag Manubhai Shah as an Additional Director of the Company in the capacity of Independent Director for a term of 5 years with effect from June 27, 2020, subject to the approval of the Members of the Company.

In terms of section 160 of the Companies Act, 2013, the Board Governance, Nomination and Compensation Committee and the Board have recommended the

appointment of Mr. Parag Manubhai Shah as an Independent Director pursuant to the provisions of Sections 149 and 152 of the Companies Act, 2013. The Company has also received a notice in writing from a member proposing the candidature of Mr. Parag Manubhai Shah to be appointed as Director of the Company.

The Company has received a declaration from Mr. Parag Manubhai Shah confirming that he meets the criteria of independence under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, the Company has also received Mr. Parag Manubhai Shah consent to act as a Director in terms of section 152 of the Companies Act, 2013 and a declaration that he is not disqualified from being appointed as a Director in terms of Section 164 of the Companies Act, 2013.

In the opinion of the Board, Mr. Parag Manubhai Shah fulfils the conditions specified in the Companies Act, 2013 and rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for his appointment as an Independent Director of the Company and he is independent of the management

Except Mr. Parag Manubhai Shah, being the appointee, or his relatives, none of the Directors and Key Managerial Personnel of the Company or their relatives are concerned or interested financially or otherwise, in the resolution set out at Item No. 3.

The Board of Directors recommends the resolution in relation to appointment of Mr. Parag Manubhai Shah as an Independent Director of the Company, as set out in Item No. 3 for approval of the members by way of a Ordinary Resolution. Additional Information required pursuant to SS – 2 is as under:

Name of the Director	Parag Manubhai Shah
Father's Name	Manubhai Shantilal Shah
Date of Birth	12/05/1954
Qualification	Graduation (B.Sc)
Date of Joining the Board of Director of the Company	27 th June 2020
Number of Shares held in the Company	Nil
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board	Nil

Other Chairmanship / Membership of Committees of Board of other Companies	Nil
Specific Functional Area	<p>Mr. Parag Manubhai Shah is a experienced person. He is Bachelor of Science and has vast experience in the field of the Printing and Management of the Business of the Company. He also has enough experience in the field of legal and accountancy matters.</p> <p>Looking to the Profile and experience of the Company, the appointment of Mr. Parag Manubhai Shah will be very useful in maintain the balance between independent and non-independent directors</p>
Relationship with Directors / inter-se KMP	None
Experience	He has experience of more than 20 years. He is Bachelor of Science and has vast experience in the field of the Printing and Management of the Business of the Company. He also has enough experience in the field of legal and accountancy matters.
Terms and Conditions of appointment	Upto 5 years commencing from 27/6/2020
Remuneration sought to be paid and last drawn	Nil. However the Board of Directors is at liberty to pay remuneration within the limits of Companies Act 2013.
Number of meeting of Board of Directors attended during the year	Nil meeting attended during year 2019 – 2020.

Item No. 4

It is proposed to increase the authorized Share Capital of the Company in order to enable the Company to increase its Paid up Share Capital. It is proposed to increase the authorized share capital of the Company from Rs. 6.00 Crores to Rs. 11.25 Crores

In order to enable the Company to increase the authorized Share Capital, the proposed Special resolution is put for the approval of the members. It is proposed to alter the Clause V of the Memorandum of Association of the Company.

Hence the resolution is put for the approval of the members.

None of the Directors, Key Managerial Personnel or their relatives are in any way concerned or interested, financially or otherwise in this resolution.

Item No. 5

In order to improve the liquidity of the Company's shares in the stock market and also to encourage participation of retail investors in the shares of the Company, the Board of Directors of the Company at their meeting held on August 24, 2020, have recommended that amount standing to the credit of securities premium account and free reserves, be applied for issue of bonus shares to the members of the Company in the proportion of 1 (one) fully paid up bonus equity share of Rs. 10- each for every 1 (one) fully paid up equity share of Rs. 10- each held on the record date to be determined by the Board. These bonus shares shall rank pari passu in all respects with existing equity shares including dividend. The Board recommends the Resolution at Item No. 6 for issue of Bonus Shares.

None of the Directors / Key Managerial Personnel or their relatives is concerned or interested in the resolution except to the extent of their shareholding in the Company, if any.

Item No. 6

The Board on the recommendation of the Audit Committee has approved the appointment of M/s. P.H. Desai & Co. Cost Auditors at remuneration of Rs. 25,000/- to conduct the audit of the cost records of the Company for the financial year ending March 31, 2021. In accordance with the provisions of the Sec 148 of the Act read with the Companies (Audit & Auditors) Rules, 2014, the Board recommends the approval for appointment and remuneration payable to the Cost Auditors. The Directors recommends the resolution for members' approval as an Ordinary Resolution.

None of the Directors, Key Managerial Personnel or their relatives are in any way concerned or interested, financially or otherwise in this resolution.

Item No. 7

Pursuant to Section 188 of the Companies Act, 2013, read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014, the Company is required to obtain consent of Board of Directors and prior approval of the members by way of Ordinary Resolution, in case certain transactions with related parties exceeds such sum as is specified in the Rules made thereunder from time to time. The aforesaid provisions are not applicable in respect of transactions entered into by the Company in the ordinary course of business on an arm's length basis.

However, pursuant to Regulation 23 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, approval of the members through Ordinary Resolution is required for related party transactions, even if they are entered into in the ordinary course of business and on arm's length basis. For this purpose, a transaction is considered material, if the transaction/transactions to be entered into individually or taken together with previous transactions during a financial year exceed 10% of the annual turnover of the Company, as per the last audited financial statements of the Company.

All the Related Party Transactions entered / proposed to be entered into by the Company are at arm's length basis and in the ordinary course of business and approval of the Audit Committee / Board is obtained, wherever required.

The Company has existing transactions with its related party, which is in the ordinary course of business and at arm's length basis. However, the value of transactions with related party in respect of upcoming financial years and the estimated value of transaction are likely to exceed 10% of the annual turnover of the Company, based on the audited financial statements for year ended 31st March, 2020.

Accordingly, on recommendation of the Audit Committee and Meeting of the Board of Directors held on 29th June, 2020 approved related party transactions and it is proposed to seek approval of the members by way of Ordinary Resolution under Section 188 of the Companies Act, 2013, the Companies (Meeting of Board and its Power) Rules, 2014 and SEBI (LODR) Regulations, 2015 to enable the Company to enter into following related party transactions in one or more tranches.

The particulars of the contract / transactions with its related party are as under:

Name of the Related Party	Nature of Relationship	Nature of Transaction proposed to be entered
B. Chokshi Chem Private Limited	A Company in which Mr. Shalin Chokshi is interested directly or indirectly. Mr. Shalin Chokshi together with its relatives hold 100% share capital of B. Chokshi Chem Private Limited.	Sale, Purchase or supply of any goods or material

The Aggregate value of transactions of the Company with per related party does not exceed 50 Crore Rupees per year. The approval is being sought for a period of 5 (five) financial years.

Mr. Shalin Chokshi is deemed to be interested in the proposed resolution. Other than this none of other directors, Key Managerial Personnel or their relatives are directly or indirectly concerned or interested, financially or otherwise, except to the extent of his/ her respective shareholding, if any, in the Company, in the resolution set out in item No. 7 of the Notice.

The Board recommends the Ordinary Resolution at Item No. 7 of the Notice for approval of the Members.

ARVEE LABORATORIES (INDIA) LIMITED

DIRECTOR`S REPORT

To
The Members of,
ARVEE LABORATORIES (INDIA) LIMITED
Ahmedabad

Your Directors have pleasure in presenting the 9th Annual Report and Audited Statement of Accounts for the year ended on 31st March 2020 with Auditor`s Report thereon.

Financial Highlights

(Rs. In Lacs)

Particulars	2019 – 2020	2018 - 2019
Revenue from Operations	4541.87	5490.18
Other Income	34.60	35.39
Total Revenue	4576.47	5525.58
Depreciation	228.90	235.05
Financial Expenses	98.77	163.37
Profit before Tax	309.05	254.41
Tax Expense -		
Current Tax	100.77	43.15
Prior Period Taxes	0	1.56
Deferred Tax	(14.41)	(16.59)
Profit After Tax	222.69	226.28

Turnover has declined in comparison to the previous year. Profit after tax has declined marginally.

The Company is taking all the possible steps to increase the profitability.

Transfer to Reserves :

The Opening Balance of Reserves and Surplus is Rs. 1095.18 Lacs. The whole of the net Profit of Rs. 222.69 lacs is transferred to the Reserves and Surplus. The Closing Balance of Reserves & Surplus is of Rs. 1317.88 lacs.

Dividend :

In order to conserve resources, your Directors do not recommended dividend for the year 2019-20 on Equity Shares of the Company.

Details regarding Energy Conservation :

Pursuant to Rule 8 (3) of Companies (Accounts) Rules, 2014, the Board of Directors hereby statge as under declare that.

A. CONSERVATION OF ENERGY:

Power & Fuel Consumption:	Current Year
Electricity:	
i) Purchased:	
(a) Units	12,14,748 units
(b) Amount	91,76,209.80
(c) Units/per liter of Diesel Oil	--
(d) Cost per unit (Rs.)	7.55/Unit
ii) Own Generation:	
(a) Units	--
(b) Amount	--
(c) Units/per liter of Diesel Oil	--
(d) Cost per unit (Rs.)	--
iii) Windmill Turbine:	
(a) Units	--
(b) Amount	--

Steps taken or impact on conservation of energy.

In line with the Company's commitment towards conservation of energy, all units continue with their efforts aimed at improving energy efficiency through innovative measures to reduce wastage and optimize consumption. Some of the measures taken by the Company in this direction at its units located at areas under:

- a. We have made optimum use of electrical motors and day light resources at plant.
- b. Installation of LEDs at several locations.

The steps taken by the company for utilising alternate sources of energy:

NIL

Details regarding Technology Absorption :

Pursuant to Rule 8 (3) of Companies (Accounts) Rules, 2014, the Board of Directors hereby declare that there are no particulars to report for Technology Absorption. However the Company takes help of the technical consultants from time to time.

Details regarding Foreign Exchange Earnings and Outgo :

The details regarding foreign exchange earnings and outgo are provided in the note no. 32 to the financial Statement. Members are requested to refer the same.

Disclosure of Directors Responsibility Statement :

As required u/s 134 (5) of the Companies Act, 2013 the Directors hereby state and confirm:

- i. In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any.
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year as on 31/03/2020 and of the profit of the company for that period.
- iii. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
- iv. The Directors have prepared the annual accounts on a going concern basis.
- v. The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- vi. The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Listing:

The Equity Shares of your Company are listed on Emerge Platform of National Stock Exchange of India Limited. The Company has paid necessary listing fees for the year 2020 – 2021.

Details of Material Changes and Commitments, Occurred during the Period affecting financial position of the Company:

During the year under review there were no significant and material orders passed by any Regulators or Court or Tribunals which may have impact on the going concern status. No order has been passed by any Regulators or Court or Tribunals which may have impact on the Company's operation in future. Further there is no material changes and commitments occurred subsequent to the Balance sheet till date of report.

Particulars of Loans, Guarantees and Investments under Section 186 of the Companies Act, 2013:

The Company has not provided any guarantee or provided any Security to any Person for the loans availed by others. The details regarding the Loans and Advances, Investments, if any, are provided in the Balance Sheet.

Particulars of Contracts or Arrangements with Related Parties under Section 188 of the Companies Act, 2013 :

All contracts / arrangements / transactions, if any, entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company has entered into transactions with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions.

No advance is paid to any related party (other than loans and advances) for entering any transaction. No Bad Debts of related parties.

The details of the related party transactions are disclosed in note 29 to the financial statement which sets out related party disclosures. The requisite details are also provided in form AOC – 2 which forms part of the report.

Disclosure of Companies covered under Section 178 (1) on Directors appointment and Remuneration including matters referred under Section 178 (3) of Companies Act, 2013 and Details of Statement indicating manner in which formal annual evaluation made by Board of its Performance and of its Committees and individual Directors:

The Company has devised a Policy for Directors; appointment and remuneration including criteria for determining qualifications, performance evaluation and other matters of Independent Directors, Board, Committees and other individual Directors which include criteria for performance evaluation of both non-executive directors and executive directors.

The Company's Nomination & Remuneration policy which includes the Director's appointment & remuneration and criteria for determining qualifications, positive attributes, independence of the Director & other matters is attached as Annexure- I to this Report and the same is also available on the website of the Company at the link www.arveelabs.com

Declaration by Independent Directors:

The Independent Directors of the Company namely Vishal Nitin Mehta, Chandrakala Ashok Bhatt and Parag Manubahi Shah (w.e.f. 27th June 2020) have confirmed to the Board that they meet the criteria of independence as specified under Section 149 (6) of the Companies Act, 2013 and they qualify to be independent directors. They have also confirmed that they meet the requirements of independent directors as specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Auditors and Audit Report :

At the 7th Annual General Meeting of the Company KCJM & Associates, Chartered Accountants, Ahmedabad were appointed as Statutory auditors for a period of five years including for the financial year 2017 – 2018. Pursuant to the notification issued by MCA ratification is not required at each annual general meeting.

There is no qualification or adverse remarks made by the auditors in their report.

Cost Audit and Cost Records:

The Company has maintained adequate Cost records required to be maintained in terms of the Companies Act, 2013.

P.H. Desai & Co., acts as a Cost Auditor for the financial year 2019 – 2020 and also for the year 2020 - 2021.

Disclosure of Risk Management Policy :

The Company has a structured risk management policy. The Risk management process is designed to safeguard the organization from various risks through adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in order to minimize its impact on the business. The potential risks are inventorised and integrated with the management process such that they receive the necessary consideration during decision making.

SECRETARIAL AUDIT

The Company has obtained a Secretarial Audit Report M/s. Jalan Alkesh & Associates, Company Secretary in Practice to conduct the secretarial audit for the financial year 2019-20. Secretarial Audit is attached and marked as Annexure II.

In the opinion of the Board there is no qualification or adverse remarks.

Board Meetings:

During the year under review, 6 (Six) Board meetings were held. The dates of Board meetings and attendance details are as under

Sr. No.	Date of Board Meeting	No. of Directors entitled to attend	No. of Directors who have attended the meeting	Name of the Director who Attended
1	27 th May 2019	6	6	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mr. Saumil Bharatbhai Chokshi 4. Mrs. Chandrakala Ashok Bhatt 5. Mr. Amishkumar Maheshkumar Shah 6. Mr. Vishal Nitin Mehta
2	10 th July, 2019	5	5	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Amishkumar Maheshkumar Shah 5. Mr. Vishal Nitin Mehta
3	23 rd October, 2019	4	4	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Vishal Nitin Mehta
4	14 th November, 2019	4	4	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Vishal Nitin Mehta
5	16 th January, 2020	4	4	1. Mr. Shalin Sudharkbhai Patel 2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Vishal Nitin Mehta
6	20 th March, 2020	4	4	1. Mr. Shalin Sudharkbhai Patel

				2. Mr. Shalin Bharat Chokshi 3. Mrs. Chandrakala Ashok Bhatt 4. Mr. Vishal Nitin Mehta
--	--	--	--	--

In respect of the above board meetings adequate notice was given to all the Directors together with the agenda. The gap between two Board meetings does not exceed 120 days. Independent Directors meeting was held on 27th May, 2019.

Corporate Governance:

Since the Company securities are listed on emerge platform of NSE, by virtue of Regulation 15 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance of corporate governance provisions as specified in regulation 17 to 27 and clauses (b) to (i) of sub – regulation (2) of Regulation 46 and para C, D and E of Schedule V are not applicable to the Company. Hence Corporate Governance requirement do not apply.

Management Discussion and Analysis Report

Management Discussion and Analysis Report as required under Regulation 34 and Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith and marked as Annexure III.

Code of Conduct

The Board of Directors has already adopted the Code of Ethics and Business Conduct for the Directors and Senior Management personnel. This code is a comprehensive code applicable to all Directors, Executive as well as Non – executive and members of the Senior Management. The Code has been circulated to all the members of the Board and Senior Management Personnel and compliance of the same has been affirmed by them.

A declaration given by the Managing Director and CEO is given below:

The Company has obtained from all the members of the Board and Senior Management Personnel of the Company, affirmation that they have complied with the Code of Ethics and Business Conduct framed for Directors and Senior Management Personnel in respect of the financial year 2019-2020.”

The company has adopted a Code of Conduct for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated employees of the Company and can be accessed at www.arveelabs.com

Dematerialization of Shares:

100% Equity Shares of the Company are in demat form.

Policies :

Various policies required under the provision of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 are adopted and uploaded on the website of the Company namely www.arveelabs.com

Committees:**a. Audit Committee:**

Audit Committee as per the provisions of Section 177 of the Companies Act, 2013 and Regulation 18 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 have been constituted with effect from 4th December, 2017.

Role of the audit committee

1. Overseeing the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible.
2. Recommending to the Board, the appointment, re-appointment and, if required, the replacement or removal of the statutory auditor and the fixation of audit fees.
3. Approval of payment to statutory auditors for any other services rendered by the statutory auditors.
4. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to:
 - a. Matters required to be included in the Directors Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013.
 - b. Changes, if any, in accounting policies and practices and reasons for the same.
 - c. Major accounting entries involving estimates based on the exercise of judgment by management.
 - d. Significant adjustments made in the financial statements arising out of audit findings.
 - e. Compliance with listing and other legal requirements relating to financial statements.
 - f. Disclosure of any related party transactions.
 - g. Modified opinion(s) in the draft audit report.

5. Reviewing, with the management, the half yearly and annual financial statements before submission to the board for approval.
6. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter.
7. Reviewing and monitoring the auditor's independence and performance and effectiveness of audit process.
8. Approval of any transactions of the Company with Related Parties, including any subsequent modification thereof.
9. Scrutiny of inter-corporate loans and investments.
10. Valuation of undertakings or assets of the Company, wherever it is necessary.
11. Evaluation of internal financial controls and risk management systems.
12. Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems.
13. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
14. Discussion with internal auditors on any significant findings and follow up there on.
15. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.
16. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
17. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
18. To review the functioning of the Whistle Blower mechanism, in case the same exists.
19. Approval of appointment of Chief Financial Officer or any other person heading the finance function or discharging that function after assessing the qualifications, experience & background, etc. of the candidate.

20. To overview the Vigil Mechanism of the Company and took appropriate actions in case of repeated frivolous complaints against any Director or Employee.

21. Monitoring the end use of funds raised through public offers and related matters.

The Audit Committee shall mandatorily review the following information:

1. Management Discussion and Analysis of financial condition and results of operations.

2. Statement of significant related party transactions (as defined by the Audit Committee), submitted by management.

3. Management letters / letters of internal control weaknesses issued by the statutory auditors.

4. Internal audit reports relating to internal control weaknesses.

5. The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.

6. Statement of deviations:

a) Half yearly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).

b) Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

Powers of the Audit Committee

- ⊙ Investigating any activity within its terms of reference;
- ⊙ Seeking information from any employee;
- ⊙ Obtaining outside legal or other professional advice; and
- ⊙ Securing attendance of outsiders with relevant expertise, if it considers necessary.

The composition of audit committee is as under

Name of the Director	Designation
Vishal Nitin Mehta	Independent Director
Amishkumar Maheshkumar Shah (upto 26.9.2019)	Independent Director
Shalin Sudhakarbhai Patel	Managing Director

Vishal Nitin Mehta acts as a Chairman of the Committee.

The Company Secretary of the Company acts as the Secretary to the Audit committee. All the recommendations of the audit committee have been accepted.

The audit Committee met on

Date of Audit Committee Meeting	No of Directors entitled to attend the meeting	No. of Directors attending the meeting	Attended by Director
27 th May 2019	3	3	1. Mr. Vishal Nitin Mehta 2. Mr. Amishkumar Shah 3. Mr. Shalin Patel
10 th July, 2019	3	3	1. Mr. Vishal Nitin Mehta 2. Mr. Amishkumar Shah 3. Mr. Shalin Patel
1 st October, 2019	2	2	1. Mr. Vishal Nitin Mehta 2. Mr. Shalin Patel
14 th November, 2019	2	2	1. Mr. Vishal Nitin Mehta 2. Mr. Shalin Patel

Stakeholders Committee:

The Stakeholders Relationship Committee was constituted as per the provisions of Section 178(5) of the Companies Act, 2013 and Regulation 20 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 vide resolution passed at the meeting of the Board of Directors held December 04, 2017. The terms of reference of the Stakeholders Relationship Committee include the following:

1. Redressal of shareholders'/investors' complaints.

2. Reviewing on a periodic basis the approval of transfer or transmission of shares, debentures or any other securities made by the Registrar and Share Transfer Agent;
3. Issue of duplicate certificates and new certificates on split/consolidation/renewal.
4. Non-receipt of declared dividends, balance sheets of the Company.
5. Carrying out any other function as prescribed under the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The composition of Stakeholders Relationship Committee is as under :

Name of the Director	Status in Stakeholders Relationship Committee
Mr. Amishkumar Maheshkumar Shah (upto 26.9.2019)	Chairman
Mr. Shalin Bharat Chokshi	Member
Mr. Saumil Bharatbhai Chokshi (upto 24.6.2019)	Member

The Company Secretary acts as a secretary of the Committee. All recommendations of Stakeholders Committee have been accepted by the Board.

The Stakeholders Committee met 2 times on

Date of Meeting of Stakeholders Committee	No. of Directors entitled to attend the meeting	No. of Directors attending the meeting	Attended by Directors
3 rd May, 2019	3	3	1. Shri Amishkumar Shah 2. Shri Shalin Chokshi 3. Shri Saumil Chokshi
6 th September, 2019	2	2	1. Shri Amishkumar Shah 2. Shri Shalin Chokshi

Nomination and Remuneration Committee:

The constitution of the Nomination and Remuneration Committee as per the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 was approved by a Meeting of the Board of Directors held on December 04, 2017.

The role of Nomination and Remuneration Committee is as under :

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy relating to, the remuneration of the directors, Key Managerial Personnel and other employees.
2. Formulation of criteria for evaluation of performance of Independent Directors and the Board of Directors.
3. Devising a policy on diversity of Board of Directors.
4. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal.
5. Whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.
6. Such other matters as may from time to time be required by any statutory, contractual or other regulatory requirements to be attended to by such committee.

The composition of Nomination and Remuneration Committee is as under

Name of the Director	Status in Stakeholders Relationship Committee
Chandrakala Ashok Bhatt	Chairman
Mr. Vishal Nitin Mehta	Member
Mr. Saumil Bharatbhai Chokshi (upto 24.6.2019)	Member

The Company Secretary acts as a secretary of the Committee.

Date of Meeting of Nomination and	No. of Directors entitled to	No. of Directors	Name of the Director attending the meeting
-----------------------------------	------------------------------	------------------	--

Remuneration Committee	attend the meeting	attended the meeting	
3 rd May, 2019	3	3	1. Smt. Chandrakala Ashok Bhatt 2. Shri Vishal Nitin Mehta 3. Shri Saumil Bharat Chokshi
17 th January, 2020	2	2	1. Smt. Chandrakala Ashok Bhatt 2. Shri Vishal Nitin Mehta

All the recommendation of Nomination and Remuneration Committee were accepted by the Board.

COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND GENERAL MEETINGS

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (ICSI).

Corporate Social Responsibility :

The Company do not fall under the Criteria of Section 135 of the Companies Act, 2013.

Investor Education and Protection Fund:

No amount was required to be transferred to Investor Education and Protection Fund.

Disclosure under Rule 8 (5) of Companies Accounts Rules, 2014 :

a) Disclosure of financial Summary / Highlights :

Particulars	2019 – 2020	2018 - 2019
Revenue from Operations	4541.87	5490.18
Other Income	34.60	35.39
Total Revenue	4576.47	5525.58
Depreciation	228.90	235.05
Financial Expenses	98.77	163.37

Profit before Tax	309.05	254.41
Tax Expense -		
Current Tax	100.77	43.15
Prior Period Taxes	0	1.56
Deferred Tax	(14.41)	(16.59)
Profit After Tax	222.69	226.28

The Company is taking all the possible steps to increase the profitability.

b) Disclosure of Change in Nature of Business :

The Company is engaged in Chemicals. There is no change in nature of Company Business.

c) Details of Directors / Key Managerial Personnel Appointed / Resigned:

During the year under the review, no Directors / Key Managerial Personnel was appointed.

During the year under the review, following Director have resigned.

- a. Mr. Saumil Bharat Chokshi has resigned as Director of the Company with effect from 24th June, 2019.
- b. Mr. Amishkumar Maheshkumar Shah has resigned as a Director of the Company with effect from 26th September, 2019.

d) Details of Holding / Subsidiary Companies / Joint Ventures / Associate Companies:

During the year under review, the Company has no holding / subsidiary companies / joint ventures / associate companies.

e) Details regarding Deposit covered under Chapter V of the Companies Act, 2013.

The Company has not invited any deposit other than the exempted deposit as prescribed under the provision of the Companies Act, 2013 and the rules framed there under, as amended from time to time. Hence there are no particulars to report about the deposit falling under Rule 8 (5) (v) and (VI) of Companies (Accounts) Rules, 2014

f) Details of Deposit which are not in compliance with requirements of Chapter V of the Act.

Not Applicable

g) Details of Significant and Material Orders passed by Regulators or Courts or Tribunals.

There are no material changes and commitments, if any, affecting the financial position of the Company between the financial years end of the Company and date of the report.

h) Internal financial Controls.

The Company has identified and documented all key internal financial controls, which impact the financial statements. The financial controls are tested for operating effectiveness through ongoing monitoring and review process of the management and independently by the Internal Auditors. In our view the Internal Financial Controls, affecting the financial statements are adequate and are operating effectively.

FormNo.MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED
ON 31ST MARCH, 2020.

*[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the
Companies (Management and Administration) Rules, 2014]*

I. REGISTRATION AND OTHER DETAILS:

I	CIN	L24231GJ2012PLC068778
Ii	Registration Date	27/01/2012
Iii	Name of the Company	ARVEE LABORATORIES (INDIA) LIMITED
Iv	Category/Sub-Category of the Company	Indian Non Government Company / Company Limited by Shares
V	Address of the Registered office and contact details	403, Entice, Nr. Jayantilal Park BRTS, Iscon Bopal Road, Ambli, Ahmedabad, Gujarat India 380058 shalin.patel@arveelabs.com
Vi	Whether listed company	Yes
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai – 400059 Tel: +91 22 62638200

h) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total(B)(1)	0	0	0	0	0	0	0	0	0
2. Non Institutions	0								
a) Bodies Corp.	102000	0	102000	1.85	110000		110000	2.00	0.15
(i) Indian									
(ii) Overseas									
b) Individuals									
(i) Individual shareholders holding nominal share capital uptoRs. 1 lakh	134000	0	134000	2.43	126000	0	126000	2.29	-0.15
(ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	1212000	0	1212000	22.00	1212000	0	1212000	22.00	0.00
c) Others (NRIS)	4000	0	4000	0.07	4000	0	4000	0.07	0.00
HUF	8000	0	8000	0.15	8000	0	8000	0.15	0
Sub-total(B)(2)	1460000	0	1460000	26.5	1460000	0	1460000	26.50	0

Total Public Shareholding (B)=(B)(1)+ (B)(2)	1460000	0	1460000	26.5	1460000	0	1460000	26.50	0
C. Shares held by Custodian for GDRs &ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	5510000	0	5510000	100	5510000	0	5510000	100	

ii.Shareholding of Promoters

Sr. No.	Shareholder Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbe red to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbe red to total shares	
1	Bharatbhai R. Chokshi	685000	12.43	0	685000	12.43	0	0
2	Saumilbhai B. Chokshi	669000	12.14	0	669000	12.14	0	0
3	Shalinbhai B. Chokshi	669000	12.14	0	669000	12.14	0	0
4	Shalin S. Patel	1690000	30.67	0	1690000	30.67	0	0

5	Sudhakar C. Patel	331000	6.01	0	331000	6.01	0	0
6	Sudhakar C. Patel, HUF	1000	0.02	0	1000	0.02	0	0
7	Shalin S. Patel, huf	1000	0.02	0	1000	0.02	0	0
8	Khushbu S. Patel	1000	0.02	0	1000	0.02	0	0
9	Foram S. Chokshi	1000	0.02	0	1000	0.02	0	0
10	Kavita S. Chokshi	1000	0.02	0	1000	0.02	0	0
11	Chandrabalben S. Patel	1000	0.02	0	1000	0.02	0	0

iii. Change in Promoters' Shareholding (please specify, if there is no change)

Sr. No.	Name of the Shareholder	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total shares of the Company	No. of Shares	% of total shares of the Company
1	Bharatbhai R. Chokshi	685000	12.43	685000	12.43
2	Saumilbhai B. Chokshi	669000	12.14	669000	12.14
3	Shalinbhai B. Chokshi	669000	12.14	669000	12.14
4	Shalin S. Patel	1690000	30.67	1690000	30.67
5	Sudhakar C. Patel	331000	6.01	331000	6.01
6	Sudhakar C. Patel, HUF	1000	0.02	1000	0.02
7	Shalin S. Patel, huf	1000	0.02	1000	0.02
8	Khushbu S. Patel	1000	0.02	1000	0.02
9	Foram S. Chokshi	1000	0.02	1000	0.02

10	Kavita S. Chokshi	1000	0.02	1000	0.02
11	Chandrabalben S. Patel	1000	0.02	1000	0.02

(iv) Shareholding pattern of top ten shareholders (other than Promoters and Directors)

SR NO	Name	Shareholding		Date	Increase / Decrease in Share holding	Reason	Cumulative Shareholding during the year	
		No. of Shares At the Beginning (30/03/2019)/ end of the year (31/03/2020)	% total Shares of the Company				No of Shares	% total Shares of the company
1	GITABEN D PATEL	550000	9.98	30-Mar-2019	0		550000	9.98
		550000	9.98	31-Mar-2020	0		550000	9.98
2	JASHBHAI CHHOTABHAI PATEL	264000	4.79	30-Mar-2019	0		264000	4.79
		264000	4.79	31-Mar-2020	0		264000	4.79
3	MADHUBEN JASHBHAI PATEL	204000	3.70	30-Mar-2019	0		204000	3.70
		204000	3.70	31-Mar-2020	0		204000	3.70
4	PRANAV M PATEL	194000	3.52	30-Mar-2019	0		194000	3.52
		194000	3.52	31-Mar-2020	0		194000	3.52
5	WEALTH FIRST PORTFOLIO MANAGERS	102000	1.85	30-Mar-2019	0		102000	1.85
			1.89	07-Jun-2019	2000	Buy	104000	1.89
			1.92	26-Jul-2019	2000	Buy	106000	1.92
			1.96	02-Aug-2019	2000	Buy	108000	1.96
			2.00	20-Mar-2020	2000	Buy	110000	2.00
		110000	2.00	31-Mar-2020	0		110000	2.00
6	PATEL ALPA JAYANTILAL	8000	0.15	30-Mar-2019	0		8000	0.15
		8000	0.15	31-Mar-2020	0		8000	0.15
7	PATEL ASHI HARSHAD	6000	0.11	30-Mar-2019	0		6000	0.11
		6000	0.11	31-Mar-2020	0		6000	0.11
8	DILIP BABULAL SHAH	6000	0.11	30-Mar-2019	0		6000	0.11
		6000	0.11	31-Mar-2020	0		6000	0.11
9	POOJA GAUTAM SHAH	4000	0.07	30-Mar-2019	0		4000	0.07
		4000	0.07	31-Mar-2020	0		4000	0.07
10	RITABEN HARSHADBHAI PATEL	4000	0.07	30-Mar-2019	0		4000	0.07
		4000	0.07	31-Mar-2020	0		4000	0.07
11	SURESH KUMAR RAI	4000	0.07	30-Mar-2019	0		4000	0.07

		4000	0.07	31-Mar-2020	0		4000	0.07
12	SHAH DILIP B	4000	0.07	30-Mar-2019	0		4000	0.07
		4000	0.07	31-Mar-2020	0		4000	0.07

(v) Shareholding of Directors and Key Managerial personnel (other than Promoters)

Sl. no		Shareholding at the beginning of the year		Shareholding at the end of the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Shalin Bharat Chokshi	669000	16.52	669000	12.14
2	Saumil Bharatbhai Chokshi	669000	16.52	669000	12.14
3	Shalin Sudhakarbhai Patel	1690000	41.73	1690000	30.67
4	Chandrakala Ashok Bhatt	0	0	0	0
5	Vishal Nitin Mehta	0	0	0	0
6	Amishkumar Shah	0	0	0	0
7	Saurin Gandhi	2000	0.04	2000	0.04
8	Raina Singh Chauhan	0	0	0	0

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	117478048	1,12,50,000	0	12,87,28,048
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total(i+ii+iii)	117478048	1,12,50,000	0	12,87,28,048

Change in Indebtedness during the financial year				
- Addition	0	0	0	0
- (Reduction)	(90060613)	0	0	(90060613)
Net Change	(90060613)	0	0	(90060613)
Indebtedness at the end of the financial year				
i) Principal Amount	27417435	1,12,50,000	0	38667435
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	27417435	1,12,50,000	0	38667435

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

Sr. No.	Particulars of Remuneration	Name of Managing Director	Name of Whole Time Director	Total Amount in Rupees
		Shalin S. Patel	Shalin B. Chokshi	
1	Gross salary			
a	Salary as per provisions contained in Section 17 (1) of the Income-tax Act, 1961	12,00,000	12,00,000	24,00,000
b	Value of perquisites u/s 17(2) Income-tax Act, 1961	0	0	0
c	Profits in lieu of salary under Section 17 (3) Income-tax Act, 1961	0	0	0
2	Stock Option	0	0	0
3	Sweat Equity	0	0	0

4	Commission - as % of profit - others, specify...	0	0	0
5	Others, please specify	39,081	39,081	78,162
	Total(A)	12,39,081	12,39,081	24,78,162
	Ceiling as per the Act	5% of Net Profits or as per Schedule III of the Companies Act, 2013	5% of Net Profits or as per Schedule III of the Companies Act, 2013	

B. Remuneration to other directors:

Sr. No.	Particulars of Remuneration	Name of the Director/Manager	Total Amount
	Independent Directors		/
	Fee for attending Board / Committee Meetings		
	Commission		
	Others – Please specify		
	Total B (1)		
	Other Non Executive Directors	NIL	
	Fee for attending Board / Committee Meetings	/	
	Commission		
	Others – Reimbursement of Expenses		
	Total B (2)		

	Total B (1 + 2)		
	<u>Overall Ceilings as per Act</u>		

C. Remuneration to Key Managerial Personnel Other Than MD/Manager/WTd

Sl. no.	Particulars of Remuneration	<u>Key Managerial Personnel</u>		
		Raina Singh chauhan – Company Secretary	Saurin Gandhi – Chief Financial Officer	<u>Total</u>
1	Gross salary			
	(a) Salary as per provisions contained in section17(1)of the Income-tax Act,1961	90,000	8,20,000	9,10,000
	(b) Value of perquisites u/s 17(2) Income-tax Act,1961			
	(c) Profits in lieu of salary under section 17(3) Income-tax Act,1961			
<u>2</u>	Stock Option			
3	Sweat Equity			
4	Commission - as % of profit -others, specify...			
5	Others, please specify Leave Encashment	0	15,432	15,432
	Total	90,000	8,35,432	9,25,432

VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES:

Type	Section of the companies Act	Brief description	Details of Penalty/ Punishment / Compounding fees imposed	Authority[RD /NCLT/Court]	Appeal made. If any (give details)
A. Company					
Penalty					
Punishment					
Compounding					
B.Directors					
Penalty					
Punishment			NIL		
Compounding					
C.Other Officers In Default					
Penalty					
Punishment					
Compounding					

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti harassment policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee are set up at shop floor level to redress complaints received regularly and are monitored by women line supervisors who directly report to the Chairman. All employees (permanent, contractual, temporary, trainees) are covered under the policy. There was no complaint received from any employee during the financial year 2019-20 and hence no complaint is outstanding as on 31.03.2020 for redressal.

Particulars of Employees:

The Particulars of Employees required to be given pursuant to Section 197 of the Companies Act 2013 is provided in Annexure B.

Material Changes and Commitments & Changes, if any affecting the financial Position between financial year end of the Company and date of Report:

There are no material changes and commitments, if any, affecting the financial position of the Company between the financial years end of the Company and date of the report.

Non Disqualification of Directors:

A Certificate obtained from Practising Company Secretary regarding non disqualification of Directors of the Company is annexed and marked as Annexure IV.

Acknowledgement

Your Directors express their gratitude for the continued support, co-operation, and assistance received by the Company from various Central and State Government Department, Bankers and valued customers of the company.

FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED

Place: Ahmedabad

Dated: 24TH August, 2020

Sd/-

CHAIRMAN CUM MANAGING DIRECTOR

Shalin Sudharkarbhay Patel

(DIN: 01779902)

Annexure A

FORM NO. AOC – 2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

Sr. No.	Particulars	Details of transactions
a)	Name(s) of the related party & nature of relationship	No transactions / contracts were entered which were not at arm's length.
b)	Nature of contracts/arrangements/transaction	
c)	Duration of the contracts/arrangements/transaction	
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	
e)	Justification for entering into such contracts or arrangements or transactions'	
f)	Date(s) of approval by the Board	
g)	Amount paid as advances, if any :	
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of material contracts or arrangements or transactions at Arm's length basis.

Sr. No.	Particulars	Details of transactions
a)	Name(s) of the related party & nature of relationship	The Company has entered into transactions for Purchase of Goods from B Chokshi Chem Private Limited. Mr. Shalin Bharat Chokshi and Mr. Saumil Bharat Chokshi are interested directly or indirectly as Director / Shareholder, if any.
b)	Nature of contracts	Transaction for purchase of goods and sale of goods
c)	Duration of the contracts	Not Applicable

d)	Salient terms of the contracts or arrangements or transaction including the value, if any :	To supply / purchase the goods / fixed assets required on need basis at arm's length. The price is determined as per the prevailing market rate. The value of the transactions entered with the related parties is provided in the note no. 29 of the Balance Sheet of the Company.
e)	Date of approval by the Board, if any :	27 th May, 2019
f)	Amount paid as advances, if any :	Nil

FOR & ON BEHALF OF THE BOARD OF
ARVEE LABORATORIES (INDIA) LIMITED

Place: Ahmedabad

Dated: 24th August, 2020

Sd/-

-

CHAIRMAN CUM MANAGING DIRECTOR
Shalin Sudharkarbhair Patel

(DIN: 01779902)

ANNEXURE B

Details under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

A. Ratio of the remuneration of each director to the median remuneration of the employees of the company for the financial year 2019-20 are as follows:

Sr. No.	Directors	Remuneration (₹ in Lakhs)	Median Remuneration (₹ in Lakhs)	Ratio
1.	Shalin Sudhakarbhair Patel	12.39	1.36	9.11 : 1
2.	Shalin Bharatbhair Chokshi	12.39	1.36	9.11 : 1
3.	Saumil Bharatbhair Chokshi	--	--	--

B. The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year 2019-20 are as follows:

Name of the Directors, Chief Financial Officer, Chief Executive Officer, Company Secretary, Manager	Designation	Percentage increase in remuneration
Shalin Sudhakarbhair Patel	Managing Director	0.00
Shalin Bharatbhair Chokshi	Whole Time Director	0.00
Saumil Bharatbhair Chokshi	Director	Not Applicable as has ceased during the year.
Mr. Saurin Gandhi	Chief Financial Officer	Not Applicable *
Ms. Raina Singh Chauhan *	Company Secretary	Not Applicable *

* Appointed during the 2018 – 2019 year and hence % increase in remuneration is not applicable as during the previous year not employed in the respective capacity for full year.

C. The percentage increase in the median remuneration of employees in the financial year 2019-20:

(Amount in Rs)

	2019-20	2018-19	Increase (%)
Median Remuneration of Employees	1,36,400	1,02,000	33.72%

D. There were **82 Employees** on the rolls of company as on 31st March, 2020.

E. Comparison of average Percentile increase in salary of employees other than the managerial personnel and the percentage increase in the remuneration paid to managerial personnel:

(Amount in Rs)

	2019-20	2018-19	Increase (%)
Average salary of all employees (other than Managerial Personnel) calculated on per month basis	15,581	11,110	40
Managerial Personnel:			
Shalin Sudhakarbhair Patel	1,03,256.00	1,03,240	0.01
Shalin Bharatbhair Chokshi	1,03,256.00	1,03,240	0.01
Saurin Gandhi	69,170	Appointed during the 2018 – 2019 year and hence not applicable	Not Applicable *
Raina Singh	7,500	Appointed during the 2018 – 2019 year and hence not applicable	Not Applicable *

* Appointed during the 2018 – 2019 year and hence % increase in remuneration is not applicable as during the previous year not employed in the respective capacity for full year.

F. The key parameters for any variable component of remuneration availed by the directors;

There are no variable components in remuneration package availed by the directors.

G. Affirmation that the Remuneration is as per the Remuneration Policy of the Company:

It is hereby affirmed that the remuneration paid to the Directors, Key Managerial personnel and Senior Management is as per the Remuneration Policy.

H. Statement containing the particulars of employees in accordance with Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

None of the employees of the company employed throughout the financial year 2019-20 and were paid remuneration in excess of the limits prescribed. i.e. Rs. 1.02 Crores per annum.

None of the employees employed for a part of the financial year 2019-20 at a rate which, in aggregate, was in excess of Rs. 8.50 Lacs per month.

None of the employees were employed throughout the financial year or part thereof, was in receipt of remuneration in that year which, in aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

For and on behalf of Board of Directors

Date: 24th August, 2020

Shalin S. Patel

Place: Ahmedabad

Chairman & Managing Director

ANNEXURE I

This Nomination and Remuneration Policy is being formulated in compliance with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and Listing Agreement, as amended from time to time. This policy on Nomination and Remuneration of Directors, Key Managerial Personnel and Senior Management has been formulated by the Nomination and Remuneration Committee (NRC or the Committee) and has been approved by the Board of Directors.

CONSTITUTION OF THE COMMITTEE

The Board of Directors of the Company (Board) constituted the committee to be known as the Nomination and Remuneration Committee consisting of three non-executive directors out of which two shall be the Independent Directors. The Chairman of the Committee shall be an Independent Director.

OBJECTIVE AND PURPOSE OF THE POLICY

The objective of the policy is to ensure that

- The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully;
- Relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
- Remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals.

ROLE OF THE COMMITTEE:

The role of the NRC will be the following:

- To formulate criteria for determining qualifications, positive attributes and independence of a Director.
- To formulate criteria for evaluation of Independent Directors and the Board.
- To identify persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down in this policy.
- To carry out evaluation of Director's performance.
- To recommend to the Board the appointment and removal of Directors and Senior Management.
- To recommend to the Board policy relating to remuneration for Directors, Key Managerial Personnel and Senior Management.
- To devise a policy on Board diversity, composition, size.
- Succession planning for replacing Key Executives and overseeing.
- To carry out any other function as is mandated by the Board from time to time and/or enforced by any statutory notification, amendment or modification, as may be applicable.
- To perform such other functions as may be necessary or appropriate for the performance of its duties.

APPOINTMENT AND REMOVAL OF DIRECTOR, KMP AND SENIOR MANAGEMENT

The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend his/her appointment, as per Company's Policy.

A person should possess adequate qualification, expertise and experience for the position he/she is considered for appointment. The Committee has authority to decide whether qualification, expertise and experience possessed by a person is sufficient/satisfactory for the position.

The Company shall not appoint or continue the employment of any person as Whole-time Director who has attained the age of seventy years. Provided that the term of the person holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution.

TERM/TENURE

Managing Director/Whole Time Director

The Company shall appoint or re-appoint any person as Executive Chairman, Managing Director or Executive Director for a term not exceeding five years at a time. No re-appointment shall be made earlier than one year before the expiry of term.

Independent Director:

An Independent Director shall hold office for a term upto five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board's report. No Independent Director shall hold office for more than two consecutive terms of upto maximum of 5 years each, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director.

Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly. At the time of appointment of Independent Director it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-time Director of a listed company or such other number as may be prescribed under the Act.

Evaluation

The Committee shall carry out evaluation of performance of Director, KMP and Senior Management Personnel yearly or at such intervals as may be considered necessary.

REMOVAL

The Committee may recommend with reasons recorded in writing, removal of a Director, KMP or Senior Management Personnel subject to the provisions and compliance of the Companies Act, 2013, rules and regulations and the policy of the Company.

RETIREMENT

The Director, KMP and Senior Management Personnel shall retire as per the applicable provisions of the Act and the prevailing policy of the Company. The Board will have the discretion to retain the Director, KMP, Senior Management Personnel in the same position/ remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.

POLICY FOR REMUNERATION TO DIRECTORS/KMP/ SENIOR MANAGEMENT PERSONNEL

Remuneration to Managing Director/Whole Time Director:

The Remuneration/Commission etc. to be paid to Managing Director/Whole-time Directors, etc. shall be governed as per provisions of the Companies Act, 2013 and rules made there under or any other enactment for the time being in force and the approvals obtained from the Members of the Company. The Nomination and Remuneration Committee shall make such recommendations to the Board of Directors, assist may consider appropriate with regard to remuneration to Managing Director/Whole-time Directors.

Remuneration to Non-Executive /Independent Director:

The Non-Executive/Independent Directors may receive sitting fees and such other remuneration as permissible under the provisions of Companies Act, 2013. The amount of sitting fees shall be such as may be recommended by the Nomination and Remuneration Committee and approved by the Board of Directors.

All the remuneration of the Non-Executive/Independent Directors (excluding remuneration for attending meetings as prescribed under Section 197(5) of the Companies Act, 2013) shall be subject to ceiling/ limits as provided under Companies Act, 2013 and rules made there under or any other enactment for the time being in force. The amount of such remuneration shall be such as may be recommended by the Nomination and Remuneration Committee and approved by the Board of Directors or shareholders, as the case may be.

An Independent Director shall not be eligible to get Stock Options and also shall not be eligible to participate in any share based payment schemes of the Company.

Any remuneration paid to Non-Executive/Independent Directors for services rendered which are of professional in nature shall not be considered as part of the remuneration for the purposes of clause (b) above if the following conditions are satisfied:

(i) The Services are rendered by such Director in his capacity as the professional; and (ii) In the opinion of the Committee, the director possesses the requisite qualification for the practice of that profession.

Remuneration to Key Managerial Personnel and Senior Management:

The remuneration to Key Managerial Personnel and Senior Management shall consist of fixed pay and incentive any, in compliance with the provisions of the Companies Act, 2013 and in accordance with the Company's Policy.

The Committee for the purpose of administering the Employee Stock Option/Purchase Schemes, shall determine the stock options and other share based payments to be made to Key Managerial Personnel and Senior Management.

The Fixed pay shall include monthly remuneration, employer's contribution to Provident Fund, contribution to pension fund, pension schemes, etc. as decided from to time. The Incentive pay shall be decided based on the balance between performance of the Company and performance of the Key Managerial Personnel and Senior Management, to be decided annually or at such intervals as may be considered appropriate.

IMPLEMENTATION

The Committee may issue guidelines, procedures, formats, reporting mechanism and manuals in supplement and for better implementation of this policy as considered appropriate. The Committee may Delegate any of its powers to one or more of its members.

Annexure II

Form No. MR-3 for the financial year ended on 31st March, 2019

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies
(Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Arvee Laboratories (India) Limited

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Arvee Laboratories (India) Limited (hereinafter called the company).

Based on my verification of the Arvee Laboratories (India) Limited books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on 31 March, 2019 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31 March, 2019 according to the provisions of :

- (i) The Companies Act, 2013 (the Act) and the rules made there under
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings.
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-

- (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
- (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2009;
- (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
- (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 ;
- (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009
- (h) The Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998

And in general, the Company has systems, process and procedure for the compliance of Other Laws Applicable to the Company.

1. Income Tax Act, 1961
2. Goods and Service Tax Act, 2017
3. Employees Provident Fund Act
4. Employees State Insurance Act, 1948
5. Indian Contract Act, 1872
6. Negotiable Instruments Act, 1881
7. Payment of Gratuity Act, 1972
8. Payment of Bonus Act, 1965

I have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with National Stock Exchange of India Limited.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, guidelines, standards etc. mentioned above. The delay, if any, in the compliance of listing regulations were complied with by making necessary submission.

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period, there were no instances of:

- (i) Public Issue / Rights/Preferential issue of Shares/debentures/ sweat equity of the Company.
- (ii) Redemption/buy-back of securities.
- (iii) Merger/ amalgamation/ reconstruction etc.
- (iv) Foreign technical collaborations.
- (v) Approval under Section 180 of the Companies Act, 2013.

For, **JALAN ALKESH & ASSOCIATES**
COMPANY SECRETARIES

Date : 24th August, 2020
Place : Ahmedabad

Sd/-
ALKESH JALAN
PROPRIETOR
FCS : 10620
Cop No. 4580
F010620B000607810

This report is to be read with our letter of even date which is annexed as 'Annexure A' and forms an integral part of this report.

‘Annexure A’

To,
The Members of
Arvee Laboratories (India) Limited
Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial Records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these Secretarial Records based on our Audit.
2. We have followed the audit practices and processes as were appropriated to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of Financial Records and Books of Accounts of the Company.
4. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. Our examination was limited to the verification of procedures on test basis.
5. Wherever required, we have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events etc.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

	For, Jalan Alkesh & Associates
	Company Secretaries
Place: Ahmedabad	Sd/- Alkesh Jalan
Date: 24/08/2020	(Proprietor)
	Membership No. – 10620 Firm Registration No. - 4580

Annexure III

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Industry Structure and developments.

The Chemical industry in India provides several building blocks and raw materials for many industries, including textiles, paper, paints, soap and detergents, pharmaceuticals, agrochemicals etc. The Chemical industry (including fertilizers and pharmaceuticals) in India stands at USD 178 Bn as of 2019 which is expected to reach USD 304 Bn by 2024-25 at an annual growth rate of 9.3%. The global chemical industry is estimated to be worth USD 4.7 Tn. The Chemical industry in India contributes 3.4% to the global chemical industry. India's Chemical Industry ranks at the 6th position in the world and 4th position in Asia in terms of size. A large part of the growing Chemical industry is currently served through manufacturing done outside the country. India ranks 17th in the world export of chemicals (excluding pharmaceutical products) and ranks 7th in the world imports of chemicals (excluding pharmaceuticals products). The value additions in the petrochemicals chain offer immense possibilities and cater to the needs of textiles and clothing, agriculture, packaging, infrastructure, healthcare, furniture, automobiles, information technology, power, electronics and telecommunication, irrigation, drinking water, construction and a variety of other articles of daily and specialized usage amidst other emerging areas. The Indian market offers a large population and a strong export demand. In recent times, there has been a global shift towards Asia as the world's chemical manufacturing hub. Rise in GDP and purchasing power generates huge growth potential for the domestic market. Availability of a large pool of skilled science professionals. India offers world class engineering facilities and strong R&D capabilities.

The per capita consumption of chemicals is lower in India, compared to western countries, therefore presenting immense scope for new investments.

STATISTICS

The Chemical industry in India is expected to grow at 9.3% per annum to reach USD 304 Bn by FY 2025. The growth is expected to be driven by rising demand in end-use segments for Specialty Chemicals and for petrochemical intermediates. In 2017-18, the Chemical and Chemical Products industry accounted for 1.69% of the GVA, compared to 1.07% in 2016-17. The production of major chemicals and petrochemicals in 2019-20 (upto September) was 13,871 thousand metric tonnes (MT). The production of major chemicals in 2019-20 (upto September) was 5,817 thousand metric tonnes (MT). Alkali chemicals account for 71% of the total production of major chemicals in 2019-20 (upto September 2019). The production of Basic Major Petrochemicals in 2019-20 (upto September) was 5,817 thousand metric tonnes (MT). Polymers account for approximately 59% of the total production of basic major petrochemicals in 2019-20 (upto September). The value of chemicals and chemical products exported for the period 2019-20 (upto September) stood at USD 148.3 Bn. The share of export of Chemicals and Petrochemicals is 12.5% of the total national export in 2019-20 (upto September).

Major Segments of the Indian Chemical Industry

1. Base chemicals: Petrochemicals, man—made fibers, industrial gases, fertilizers, chlor - alkali and other organic and inorganic chemicals.
2. Specialty Chemicals: Dyes and pigments, leather chemicals, construction Chemicals, personal care ingredients and other specialty chemicals.

3. Pharmaceuticals: Active Pharmaceutical ingredients (API's) and formulations
4. Agrochemicals: Insecticides, herbicides, fungicides, and other crop protection Chemicals.
5. Biotechnology: Bio—pharma, bio—agri, bio—services and bio—industrial products.

Opportunities and Threats

Indian Advantage

FDI POLICY	100% FDI is allowed under the automatic route in the Chemical industry, except in the case of hazardous chemicals.
SECTOR POLICY	The Government of India has conceptualized (PETROLEUM, CHEMICALS AND PETROCHEMICAL INVESTMENT REGIONS) PCPIRs as clusters that provide investors with a transparent and investment friendly policy and facility regime. The projected investment on full realisation of PCPIRs is USD 1091.4 Bn. As of November 2018, investments worth USD 261.8 Bn have been and committed and more than 300,000 persons have been employed in direct and indirect activities related to PCPIRs.
FINANCIAL SUPPORT	
R&D INCENTIVES FOR INDUSTRY AND PRIVATE SPONSORED RESEARCH	A weighted tax deduction is given under section 35 (2AA) of the Income Tax Act. Weighted deduction of 200% is granted to assess for any sums paid to a national laboratory, university or institute of technology, or specified people with a specific direction and that the said sum is used for scientific research within a program approved by the prescribed authority.
MANUFACTURERS WITH AN IN-STATE INCENTIVES	Apart from the above, each state in India offers additional incentives for industrial projects. Incentives are in areas like subsidized land cost and relaxation in stamp duty exemption on sale/lease of land, power tariff incentives, concessional rate of interest on loans, investment subsidies/tax incentives, backward areas subsidies, special incentive packages for mega projects etc.

HOUSE R&D CENTRE	Section 35 (2AB) of the Income Tax Act, 1961 provides weighted tax deduction of 150% of the expenditure incurred by a specified company, on scientific research in the in-house R&D centres as approved by the prescribed authority. This does not include expenditure on the cost of any land or building. The weighted tax deductions of 150% are effective till 31 st March 2020. Consequent to that, the weighted tax deductions will be 100%.
EXPORT INCENTIVES	Export promotion capital goods scheme Duty drawback scheme Merchandise Export from India Scheme
AREA-BASED INCENTIVES	Incentives for units in Special Economic Zones (SEZ)/National Investment and Manufacturing Zones (NIMZ) as specified in respective Acts or setting up projects in special areas like the North-east, Jammu & Kashmir, Himachal Pradesh & Uttarakhand.
KEY POINTS IN THE UNION BUDGET 2020-21	The total allocation towards the Department Chemicals and Petrochemicals is USD 28.97 Mn. The total allocation towards the Central Institute of Plastic Engineering and Technology stands at USD 13.03 Mn. The allocation towards the Promotion of Petrochemicals stands at USD 7.13 Mn.
INVESTMENT OPPORTUNITIES FINE & SPECIALTY CHEMICALS	India produces many fine and speciality chemicals, which have very specific uses and are essential for increasing industrial production. These special chemicals find wide usage as food additives and pigments, polymer additives, anti-oxidants in the rubber industry, etc. Indian specialty chemicals industry is expected to account for 5% of Global Specialty Chemicals by 2020.

Demand Driver — Domestic and International

- The Indian chemicals industry is projected to reach \$304 bn by 2025
- Indian ranks 14th in export and 8th in import of chemicals (Excluding Pharmaceuticals products) globally
- Demand of chemical products is expected to grow at approximately 9% p.a. over the next 5 years
- Indian chemical industry employs more than 2 million people
- Total production of major chemicals and petrochemicals stood at 27,858 MT during 2018-19, a growth of 4.18% over 2017-18. Alkali chemicals had the largest share in the Chemical industry in India with approximately 69% share in the total production. Production of polymers accounts for around 61% of the total production of basic major petrochemicals.

- The petrochemical demand is expected to grow at 7.5% CAGR from FY 2019-23, with polymer demand growing at 8%
- The agrochemicals market in India is expected to grow at 8% CAGR reaching \$3.7 bn by FY22 and \$4.7 bn by FY25.
- The specialty chemicals constitute 22% of total chemicals and petrochemicals market in India. As of FY18, the total market size is around \$35 bn. The demand for speciality chemicals is expected to grow at 12% CAGR from FY19-22.

Growth Driver

- Rising disposable income, median age of population, urbanisation and growing penetration and demand from rural markets
- Shift in production and consumption towards Asian and Southeast Asian countries in all sectors leading to increasing demand for Chemicals and Petrochemicals
- Shift in consumer preferences towards a healthier lifestyle and environment-friendly products
- Opportunity to produce \$111 Bn worth of chemical products by 2023 for domestic requirements

Threats:

IMPACT OF THE COVID-19 PANDEMIC ON THE OPERATIONS AND BUSINESS:

- In view of the lockdown due to COVID-19 pandemic across the country from end March 2020 the manufacturing facilities of the Company were working partially after the first week of April 2020. As the Company is in the manufacture and sale of pharmaceuticals intermediaries after discussing with authorities and sorting out the bottlenecks the Company gradually ramped up its operations over the next several days till April end and despite manpower issues and demand made efforts to achieve optimum capacity production in May 2020. The offices and Technical Centre have been closed through April and May and those employees have been working from home wherever possible. However there was no significant impact on the business of the Company for the year ended March 31 2020. The Company is ensuring compliance with the directives issued by the Central Government State Governments and local government. All the manufacturing facilities have been sanitized so that our employees are safe and secure. All safety protocols are adhered to very stringently.
- The present economic position serves as a threat to many chemical companies both worldwide and on the regional level.
- In general labour avoid working in chemical plants. Hence company may have to face labour problem.
- Environmental Controls pose a major problem to the industry.
- Deals in explosive chemicals so utmost care is required to be taken to avoid accidents

Risks and Concerns

Your Company had put a risk management framework in place post a comprehensive review of its risk management process. Your Company takes a fresh look at the risk management framework through our Audit Committee at least once in a year. The review involved understanding the existing risk management initiatives and assessment of risks in the businesses as the relative control measures and arriving at the desired counter measures keeping in mind the risk appetite of the organization.

The audit Committee has periodically reviewed the risks in the business and recommended appropriate risk mitigating actions.
The business of the Company is likely to be affected by various internal and external risks enumerated as under:

- Our success depends largely upon the services of our Promoter, Directors and other key managerial personnel and our ability to attract and retain them.
- The prices we are able to obtain for the products that we trade depend largely on prevailing market prices.
- We face intense competition in our businesses, which may limit our growth and prospects.
- Global economic, political and social conditions may harm our ability to do business, increase our costs and negatively affect our stock price.
- Global recession and market conditions could cause our business to suffer.
- Natural calamities and changing weather conditions caused as a result of global warming could have a negative impact on the Indian economy and consequently impact our business and profitability.
- Tax rates applicable to Our Company may increase and may have an adverse impact on our business.
- Political instability or changes in the Government could adversely affect economic conditions in India generally and our business in particular.

As a responsible employer, to ensure occupational safety and employment standards, your Company maintains strict safety and quality control programs to monitor and control these operational risks.

Internal Control System and their adequacy

The Company maintains adequate internal control systems, which provides, among other things, reasonable assurance of recording the transactions of its operations in all material respects and of providing protection against significant misuse or loss of company's assets.

Internal Controls are adequately supported by internal audit and periodical review of by the management. The audit committee meets periodically to review with the management and statutory auditors, financial statements. The Audit Committee also meets with the internal auditors to review adequacy /scope of internal audit function, significant findings and follow up thereon and finding of abnormal nature.

Discussion on financial performance with respect to operational performance.

During the year company has reported total income of Rs.5525.58 lacs as against 4800.92 lacs. Net Profit of the Company during the Current year stand at Rs.108.91lacs as against profit of Rs. 223.83 lacs in the previous year.

Material developments in human resources/ Industrial Relations front, including number of people employed.

Relations with the employees of the Company at various levels remained harmonial during the year under the review. The Company is making its best efforts to retain and attract talented employees. During the year under the review, the Company has complied with all legislative provisions of labour laws. The number of employees of the company as of 31st March, 2019 was 74.

Other Disclosures:

- a. Basis of related party transaction:

During the year under the review, related party transactions, if any, are disclosed in the Balance Sheet. Transactions are entered at arm's length.

b. Disclosure of accounting treatments:

The Company has followed all relevant Accounting Standards while preparing the financial Statements.

c. Board Disclosures - Risk Management:

The Company has developed comprehensive risk management policy and same is reviewed by the Audit Committee, which in turn, informs the Board about the risk assessment and minimization procedures. Major risks identified for the Company by the management are Currency fluctuation, Compliance, Regulatory changes, Manufacturing & Supply, Litigation, Information Technology and new capital investments return. The management is however, of the view that none of the above risks may threaten the existence of the Company as robust Risk mitigation mechanism is put in place to ensure that there is nil or minimum impact on the Company in case any of these risks materialize. Since the risk control frame work is new to Indian Corporate Culture, it is being strengthened on continuous basis using the outside professional help.

d. Proceeds from public issues, right issues, preferential issues etc:

The Company came up with Public Issue during the year 2017 – 2018 of 14,60,000 Equity Shares of face value of Rs. 10/- each fully Paid Up of Arvee Laboratories (India) Limited for Cash at a Price of Rs. 61/- Per Equity Share (Including A Share Premium Of Rs. 51/- Per Equity Share Aggregating Rs. 890.60 Lakhs. The issue proceeds was applied for the purpose stated in the Prospectus.

No issue was made during the year.

Besides above, there was no instance of non-compliance of any matter related to the capital markets during the last three years.

Details of significant changes in key Financial Ratios & Return on Net worth

Pursuant to amendment made in schedule V to the Listing Regulations, details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in Key Financial Ratios and any changes in return on net worth of the Company (on standalone basis) including explanations therefor are given below:

Particulars	FY ended 31 st March, 2020	FY ended 31 st March, 2019	Changes Between CY and PY	Explanation of changes exceeding 25% in comparision to previous year
(i) Debtors Turnover	6.21%	4.61%	1.60%	Change less than 25% hence reason for

				Change not required.
(ii) Inventory Turnover	53 Days	31 Days	-22 DAYS	Since the Company has adopted the policy of having higher inventory the change has occurred
(iii) Interest Coverage Ratio	4.13	2.56	1.57	Since the earnings has gone donw in comparision to the interest payable, the interest coverage ratio is higher. It is pertinent to note that a sizeable portion is towards Unsecured loan.
(iv) Current Ratio	1.44	1.28	0.16	Change less than 25% hence reason for change not required.
(v) Debt Equity Ratio	0.24	0.86	0.62	The Company has reduced its debt and therefore the change is favourable.
(vi) Operating Profit Margin (%)	8.91%	7.56%	1.35%	Change less than 25% hence reason for change not required.
(vii) Net Profit Margin (%)	4.87%	4.10%	0.77%	Change less than 25% hence reason for change not required.
(viii) Return on Net worth (%)	40.42%	41.07%	-0.65%	Change less than 25% hence reason for change not required.

Cautionary Statement

The above Management Discussion and Analysis contains certain forward looking statements within the meaning of applicable security laws and regulations. These

pertain to the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties, regarding fluctuations in earnings, our ability to manage growth, competition, economic growth in India, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, government policies and actions with respect to investments, fiscal deficits, regulation etc. In accordance with the Code of Corporate Governance approved by the Securities and Exchange Board of India, shareholders and readers are cautioned that in the case of data and information external to the Company, no representation is made on its accuracy or comprehensiveness though the same are based on sources thought to be reliable. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time on behalf of the Company.

By Order of the Board
For, Arvee Laboratories (India) Limited

Date: 24th August, 2020
Place: Ahmedabad

Sd/-
Shalin S. Patel
Chairman and Managing Director

Certificate of Non-Disqualification of Directors

(pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (listing obligations and Requirements) Regulations, 2015)

To,
The Members of
Arvee Laboratories (India) Limited
403, Entice, Nr. Jayantilal Park BRTS,
Iscon Bopal Road, Ambli, Ahmedabad 380058

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Arvee Laboratories (India) Limited having CIN: L24231GJ2012PLC068778 and having registered office at 403, Entice, Nr. Jayantilal Park BRTS, Iscon Bopal Road, Ambli, Ahmedabad 380058 (hereinafter referred to as 'the company'), produced before us by the Company for the purpose of issuing this certificate in accordance with Regulation 34(3) read with Schedule V Para-C clause (10) (i) of the SEBI (listing obligations and Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verification (including Directors Identification Number (DIN) status at the Portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers we hereby certify that none of the Directors on the Board of the company as stated below for the Financial Year ending on 31st March, 2020 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of appointment in Company
1.	Shalin Bharatbhai Chokshi	00191903	27/01/2012
2.	Shalin Sudhakarbhai Patel	01779902	01/04/2014
3.	Vishal Nitin Mehta	07977497	04/12/2017
4.	Chandrakala Ashok Bhatt	07977517	04/12/2017

Ensuring the eligibility of for the appointment/ continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For, Jalan Alkesh & Associates
Company Secretaries

Alkesh Jalan

Place: Ahmedabad
Date: 24/08/2020

Proprietor
FCS No.: 10620
C.P. No.: 4580
UDIN : F010620B000607801

Independent Auditor's Report

To
The Members of
ARVEE LABORATORIES (INDIA) LIMITED
Ahmedabad

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **ARVEE LABORATORIES (INDIA) LIMITED**, which comprises the Balance Sheet as on 31st March, 2020, the statement of Profit and Loss Account and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India, of the state of affairs of the company as at March 31, 2020, its profit and cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to be communicated in our report.



Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Sub-section (11) of Section 143 of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the order.




2. As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) the balance sheet and the statement of profit and loss and cash flows dealt with by this Report are in agreement with the books of account;
- d) in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- e) On the basis of the written representations received from the directors as on 31 March 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2020 from being appointed as a director in terms of Section 164 (2) of the Act;
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure-B" to this report; Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- g) In our opinion, the managerial remuneration for the year ended March 31, 2020 has been paid/provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 as amended, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company does not have any pending litigations which would impact its financial position;
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W




CA KABIR MANSURI
PARTNER

MEM.NO : 126585
UDIN : 20126585AAAABC6378
PLACE : AHMEDABAD
DATE : 29-06-2020

ARVEE LABORATORIES (INDIA) LIMITED

Accounting Year: 2019-20

Annexure – A to the Independent Auditor's Report

Referred to in paragraph 1, under 'Report on Other Legal and Regulatory Requirements' section of our report of even date

1. (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
(b) The Company has a regular programme for physical verification in a phased periodic manner, which, in our opinion, is reasonable having regards to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
(c) According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds / registered sale deed provided to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date. In respect of immovable properties of land and building that have been taken on lease and disclosed as fixed assets in the financial statements, the lease agreements are in the name of the Company.
2. (a) As explained to us, Inventories have been physically verified during the year by the management at reasonable interval.
(b) In our opinion and according to the information and explanation given to us, the procedure of physical verification of inventories followed by the management is reasonable and adequate in relation to size of the company and nature of its business.
(c) In our opinion and on the basis of our examination of the records, Company is generally maintaining proper records of its inventories. No material discrepancy was noticed on physical verification of stock by the management as compared to book records.
3. According to the information and explanations given to us and on the basis of our examination of the books of account, The Company has not granted any loans, secured or unsecured, to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Consequently, the provisions of clauses (iii) are not applicable.
4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
5. According to the information and explanations given to us, The Company has not accepted any deposits the public within the meaning of section 73 to 76 and the companies (Acceptance of Deposit) Rules, 2014 (As Amended). Therefore, the provisions of the clause (v) of paragraph 3 of the Order are not applicable to the Company.
6. We have broadly reviewed the books of accounts maintained by the company pursuant to the rules made by the central government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacturing activities, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
7. In respect of statutory dues :
(a) According to the records of the Company, undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues have been generally regularly deposited with the appropriate authorities. According to the information and explanation given to us, no undisputed amounts payable in respect of the aforesaid dues were outstanding as at March 31, 2020 for a period of more than six months from the due date of becoming payable.



(b) According to the records of the Company, statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues which have not been deposited on March 31, 2020. On account of any dispute, are as follows

Name of the Statute	Nature of Dues	Amount (In Rs.)	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Income Tax	32560/-	2012-13	Commissioner of Income Tax (Appeals)

8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowing to a financial institution, bank or government or dues to debenture holders. The company has not borrowed from financial institution, government or debenture holder during the year.
9. In our opinion and according to the information and explanations given to us, moneys raised by way of debt instruments and term loans have been applied by the company for the purposes for which they were raised.
10. In our opinion and according to the information and explanations given to us, no material fraud by the company or on the company by its officers or employees has been noticed or reported during the year.
11. During the period under review, the company has paid/provided managerial remuneration in accordance with the requisite approvals mandated by the provision of section 197 read with schedule V of the Companies Act, 2013.
12. The company is not Nidhi Company and hence reporting under clause (xii) of paragraph 3 of the order is not applicable,
13. In our opinion and according to the information and explanation given to us, the company's transaction with its related party are in compliance with section 177 and 188 of the Companies Act, 2013, where applicable, and details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.
14. During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause (xiv) of paragraph 3 of the Order is not applicable to the Company.
15. In our opinion and according to the information and explanations given to us, during the year, the Company has not entered into any non-cash transactions with its Directors or persons connected to its directors and hence reporting under clause (xv) of paragraph 3 of the order is not applicable to the Company.
16. In our opinion and according to information and explanation provided to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W



CA KABIR MANSURI
PARTNER

MEM.NO : 126585
UDIN : 20126585AAAAABC6378
PLACE : AHMEDABAD
DATE : 29-06-2020

ARVEE LABORATORIES (INDIA) LIMITED

Accounting Year: 2019-20

ANNEXURE B

TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF ARVEE LABORATORIES (INDIA) LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **ARVEE LABORATORIES (INDIA) LIMITED** as of March 31, 2020 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.



Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls over Financial Reporting


Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020 with respect to the transactions of the Company, based on the internal control over financial reporting criteria established by the Bank considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

FOR KCJM & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 121324W




CA KABIR MANSURI

PARTNER

MEM.NO : 126585

UDIN : 20126585AAAABC6378

PLACE : AHMEDABAD

DATE : 29-06-2020

Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Balance Sheet as at 31st March, 2020

Particulars	Note No	As at 31.03.2020	As at 31.03.2019
EQUITY AND LIABILITIES			
Shareholder's Funds			
Share Capital	2	5,51,00,000	5,51,00,000
Reserves and Surplus	3	13,17,88,731	10,95,18,973
Non-Current Liabilities			
Long Term borrowings	4	1,95,72,064	3,46,66,376
Deferred tax liabilities (Net)		42,17,241	56,59,091
Current Liabilities			
Short-term borrowings	5	21,11,519	7,72,97,150
Trade Payables	6	10,03,76,833	6,00,06,846
Short-term provisions	7	54,19,184	66,77,677
Other current liabilities	8	1,76,63,754	2,25,68,029
Total		33,62,49,326	37,14,94,142
ASSETS			
Non-current assets			
<i>Fixed assets</i>			
Tangible assets	9	13,14,63,484	12,60,47,511
Intangible assets	9	3,58,019	4,43,519
Capital work in progress	9	1,77,92,053	2,31,60,048
Long term loans and advances	10	57,51,159	91,95,996
Current assets			
Current Investments	11	3,09,41,431	1,94,94,876
Inventories	12	6,46,78,655	4,60,94,656
Trade receivables	13	6,51,51,560	7,91,54,111
Cash and cash equivalents	14	97,84,890	3,64,79,617
Short term loans and advances	15	1,03,28,075	3,14,23,807
Total		33,62,49,326	37,14,94,142
Significant Accounting Policies	1		
The Note numbers 25 to 34 form integral part of the Financial Statements			

As per our separate report of even date attached herewith

For K C J M & Associates
Chartered Accountants


Kabir Mansuri
Partner

Membership No. 126585
FRN :- 121324W

Place : Ahmedabad

Date : 29-06-2020

UDIN : 20126585AAAABC6378




For Arvee Laboratories (India) Ltd.

Shalin S Patel
Managing Director
[DIN: 01779902]

Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]

Shalin B Chokshi
Director
[DIN: 00191903]

Raina Singh Chauhan
Company Secretary
[M. No. 57624]



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Profit and Loss Account for the year ended on 31st March, 2020

(Amount in Rs.)

Particulars	Note No	2019-20	2018-19
Revenue from operations	16	45,41,87,054	54,90,18,848
Other Income	17	34,60,682	35,39,498
Total Revenue		45,76,47,736	55,25,58,346
Expenses:			
Cost of Material Consumed	18	30,23,95,909	38,18,97,363
Changes in Inventories	19	(1,07,48,902)	1,03,15,744
Employee benefit expense	20	4,79,48,392	2,73,70,899
Financial costs	21	98,77,740	1,63,37,490
Depreciation expense	9	2,28,90,825	2,35,05,950
Other expenses			
Administrative Expenses	22	87,93,260	74,70,302
Manufacturing Expenses	23	3,21,58,584	3,98,31,522
Selling and Distribution Expenses	24	1,34,26,043	2,03,87,946
Total Expenses		42,67,41,851	52,71,17,217
Profit before exceptional and extraordinary items and tax		3,09,05,885	2,54,41,129
Exceptional & Extraordinary Items			
Profit before tax		3,09,05,885	2,54,41,129
Tax expense:			
Current tax		1,00,77,976	43,15,055
Prior Period Taxes		-	1,56,806
Deferred tax		(14,41,850)	(16,59,571)
Net Tax expenses		86,36,127	28,12,290
Profit for the period		2,22,69,758	2,26,28,839
Earning per equity share:			
(1) Basic		4.04	4.11
(2) Diluted		4.04	4.11
Significant Accounting Policies	1		
The Note numbers 25 to 34 form integral part of the Financial Statements			

As per our separate report of even date attached herewith

For K C J M & Associates
Chartered Accountants

Kabir Mansuri
Partner

Membership No. 126585
FRN :- 121324W

Place : Ahmedabad

Date : 29-06-2020

UDIN : 20126585AAAABC6378




For Arvee Laboratories (India) Ltd.

Shalin Patel
Managing Director
[DIN: 01779902]

Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]

Shalin Chokshi
Director
[DIN: 00191903]

Raina Singh Chauhan
Company Secretary
[M. No. 57624]




Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
Cash Flow Statement for the year ended 31ST March, 2020

Particulars	2019-20 Amount Rs.	2018-19 Amount Rs.
A. Cash Flow from Operating Activities		
Net Profit Before Tax	3,09,05,885	2,54,41,129
Adjustment for :		
Depreciation	2,28,90,825	2,35,05,950
Amortisation	6,14,600	6,14,600
Interest Expenses	89,07,319	1,43,87,298
Interest Income	(13,97,940)	(26,26,415)
Loss /(Gain) on Sale of Investments	(20,58,757)	(9,13,083)
Loss /(Gain) on Sale of Fixed Assets (Net)	-	-
Foreign Exchange Loss / (Gain)	-	-
Operating Profit before Working capital Changes	5,98,61,933	6,04,09,479
Adjustment for (Increase) / Decrease in Working Capital :		
Inventories	(1,85,83,999)	3,54,92,968
Trade Receivables	1,40,02,551	7,56,83,558
Loans and Advances	2,45,40,570	(1,61,61,305)
Trade Payables and Provisions	3,27,65,368	(5,74,42,597)
Cash generated from Operations	11,25,86,423	9,79,82,103
(Increase) / Decrease in Misc Expenditure	(6,14,600)	(6,14,600)
Prior Period Adjustments (Net) & Short provision of Income Tax	-	-
Direct Taxes Paid (Net)	(86,36,127)	(26,55,484)
Income Tax of earlier year	-	(1,56,806)
Net Cash from Operating Activiites	10,33,35,696	9,45,55,213
B. Cash Flow from Investing Activities :		
Purchase of Fixed Assets	(2,28,53,304)	(1,50,27,952)
Receipt of Capital Subsidy	-	25,00,000
Purchase of Investments	(1,14,46,555)	(1,94,94,876)
Profit on sale of Investment	20,58,757	9,13,083
Interest received	13,97,940	26,26,415
Net Cash used in Investing Activities	(3,08,43,162)	(2,84,83,331)
C. Cash Flow from Financing Activities :		
Share Capital Issued	-	-
Security Premium Received	-	-
Preliminary Expenses Incurred	-	-
Short term Borrowing availed	(7,51,85,631)	92,50,196
Long term Borrowings	(1,50,94,312)	(4,41,10,438)
Interest Paid	(89,07,319)	(1,43,87,298)
Net Cash used in Financing Activities	(9,91,87,262)	(4,92,47,539)
Net increase in Cash and Cash Equivalents (A+B+C)	(2,66,94,727)	1,68,24,343
Cash and Cash Equivalents as at 1st April (Opening Balance)	3,64,79,617	1,96,55,274
Cash and Cash Equivalents as at 31st March (Closing Balance)	97,84,890	3,64,79,617

Notes :

- The Cash Flow Statement has been prepared under the "Indirect Method" as set out in Accounting Standard-3 on Cash Flow Statements issued by the Institute of Chartered Accountants of India.

As per our separate report of even date attached herewith
For K C J M & Associates
Chartered Accountants



Kabir Mansuri
Partner
Membership No. 126585
FRN :- 121324W





Place : Ahmedabad
Date : 29-06-2020
UDIN : 20126585AAAABC6378

For Arvee Laboratories India Ltd.


Shalin Patel
Managing Director
[DIN: 01779902]


Shalin Chokshi
Director
[DIN: 00191903]




Saurin A Gandhi
Chief Financial Officer
[PAN: AJUPG7995F]

Raina Singh Chauhan
Company Secretary
[M. No. 57624]

Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

2. Share Capital

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Authorised				
60,00,000 (Previous year 60,00,000) Equity Shares of Rs. 10/- each		6,00,00,000		6,00,00,000
Issued, Subscribed and fully paid up				
55,10,000 (Previous year 55,10,000) Equity Shares of Rs. 10/- each		5,51,00,000		5,51,00,000
Total		5,51,00,000		5,51,00,000

a. The reconciliation of the number of Equity Shares outstanding as at 31.03.2020 and 31.03.2019 is set out

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Shares outstanding at the beginning of the year		55,10,000		55,10,000
Shares Issued during the year		-		-
Shares bought back during the year		-		-
Shares outstanding at the end of the year		55,10,000		55,10,000

During the Financial Year 2019-20, No shares were issued.

b. Terms / Rights attached to Equity Shares

The Company has only one class of equity shares having a par value of Rs.10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing annual general meeting.

During the year ended 31st March 2020, No dividend is declared by Board of Directors. (Previous year - Nil)

c. Shares held by Holding / Ultimate holding company and/or their subsidiaries/associates: Not Applicable

d. Shares reserved for issue under options: NIL

e. Aggregate number of bonus shares issued, shares issued for consideration other than cash and shares brought back during the period of five years immediately preceding the reporting date: NIL

f. Securities convertible into equity / preference shares issued along with the earliest date of conversion: NIL

g. Forfeited Shares : NIL

h. Details of Shareholders holding more than 5% shares in the company:

Name of Shareholder	As at 31 March, 2020		As at 31 March, 2019	
	No. of Shares held	% of shares held	No. of Shares held	% of shares held
Bhartbhai R. Chokshi	6,85,000	12.43%	6,85,000	12.43%
Saumilbhai B. Chokshi	6,69,000	12.14%	6,69,000	12.14%
Shalinbhai B. Chokshi	6,69,000	12.14%	6,69,000	12.14%
Shalinbhai S. Patel	16,90,000	30.67%	16,90,000	30.67%
Sudhakarbhai C. Patel	3,31,000	6.01%	3,31,000	6.01%
Total	40,44,000	73.39%	40,44,000	73.39%



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

3. Reserves and Surplus

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Securities Premium Account				
Opening balance		7,44,60,000		7,44,60,000
Add: on Fresh Issues of Equity Shares				
Closing Balance		7,44,60,000		7,44,60,000
Surplus				
Opening balance		3,50,58,973		1,24,30,134
(+) Net Profit for the current year		2,22,69,758		2,26,28,839
Closing Balance		5,73,28,731		3,50,58,973
Total		13,17,88,731		10,95,18,973

4. Long Term Borrowings

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Secured				
From bank		83,22,064		2,34,16,376
Unsecured				
Loans from Directors				
Loans from Related Parties		1,12,50,000		1,12,50,000
[Unsecured Loans are taken in pursuance of stipulation of basic requirement]				
Total		1,95,72,064		3,46,66,376

The details of security of the long term borrowings are set out below :

Description of Security offered to Standard Chartered Bank by way of Exclusive first charge of the following property/assets:

1. Hypothecation of Plant and Machinery of the company.
2. Registered Mortgage over the company's 1. R.S. No. 316 paiki Plot No 1 area admeasuring about 7183 sq mtr with construction thereon mouje kardej Ta. & Dist Bhavnagar, 2. residential flat No 403, Kailash Apartment, Nr. Gogha Circle, Bhavnagar & residential flat No 103, Pruthvi Plaza, Nr Gogha Circle, Bhavnagar.
3. First charge on entire current assets of the company including Raw Materials, Stock in process, Finished goods, spares & Receivables (not more than 90 days) present and future.
4. Personal Guarantee of Directors

Rate of Interest & Repayment terms of Loans:

1. Term Loans taken from Standard Chartered Bank bear 3MCLR+1.80 rate of interest per annum.
2. Term Loans taken from Standard Chartered Bank are repayable in 60 monthly installments.

Rate of Interest & Repayment terms of Unsecured loans taken from Directors:

1. Unsecured Loans taken from Directors bear 15% rate of interest per annum
2. Unsecured Loans taken from Directors are repayable after 5 years from the date of acceptance.

Rate of Interest & Repayment terms of Unsecured loans taken from Related parties:

1. Unsecured Loans taken from Related Parties bear 15% rate of interest per annum.
2. Unsecured Loans taken from Related Parties are repayable after 5 years from the date of acceptance.



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

5. Short Term Borrowings

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Secured				
From bank				
Cash Credit Facility		21,11,519		-
Export Packing Credit Facility		-		7,72,97,150
Unsecured				
Loans from Directors		-		-
Loans from NBFCs		-		-
Inter Corporate Deposits		-		-
Total		21,11,519		7,72,97,150

The details of security of the Short term borrowings are set out below :

Description of Security offered to Standard Chartered Bank by way of Exclusive first charge of the following property/assets:

1. Hypothecation of Plant and Machinery of the company.
2. Registered Mortgage over the company's 1. R.S. No. 316 paiki Plot No 1 area admeasuring about 7183 sq mtr with construction thereon mouje kardej Ta. & Dist Bhavnagar, 2. residential flat No 403, Kailash Apartment, Nr. Gogha Circle, Bhavnagar & residential flat No 103, Pruthvi Plaza, Nr Gogha Circle, Bhavnagar.
3. First charge on entire current assets of the company including Raw Materials, Stock in process, Finished goods, spares & Receivables (not more than 90 days) present and future.
4. Personal Guarantee of Directors

Rate of Interest & Repayment terms of Loans:

1. Cash Credit Loans taken from Standard Chartered Bank bear 1MCLR+1.70 rate of interest per annum.
2. Export Packing Credit taken from Standard Chartered Bank bear LIBOR+200BPS rate of interest per annum.
3. Short Term Loans taken from Standard Chartered Bank are repayable on demand.

6. Trade Payables

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Trade Payables		10,03,76,833		6,00,06,846
- for Capital Goods				
- Micro, Small and Medium Enterprises				
- Others	27,14,405		2,22,408	
- for Expenses				
- Micro, Small and Medium Enterprises	7,86,604		17,46,286	
- Others	55,77,003		64,23,580	
- for Goods				
- Micro, Small and Medium Enterprises	27,21,071		47,00,998	
- Others	8,85,77,750		4,69,13,574	
Total		10,03,76,833		6,00,06,846


The information regarding Micro, Small and Medium Enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the Auditors.

7. Short Term Provisions

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Others				
Provision for employees benefits		32,20,182		40,41,969
Provision for Taxation (Net of Advance Tax and Tax deducted at sources)		21,99,002		26,35,708
Total		54,19,184		66,77,677

8. Other Current Liabilities

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Current maturity of Long Term Debt		1,69,83,852		1,67,64,522
Statutory Dues		6,49,902		8,76,507
Advance From Customers		-		48,97,000
Other Current Liabilities		30,000		30,000
Total		1,76,63,754		2,25,68,029



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

NOTES TO ACCOUNTS AS ON 31ST MARCH 2020

9. Fixed Assets

9. Fixed Assets		(Amount in Rs.)						
	Name of Fixed Assets	Gross Block			Accumulated Depreciation On disposals	Net Block		
		Balance as at 1 April, 2019	Additions	(Disposals)		Balance as at 31 March, 2020	Balance as at 31 March, 2019	
	Tangible Assets							
1	Land	20,00,000	-	-	-	20,00,000	20,00,000	
2	Building	4,11,80,863	48,96,154	-	-	3,45,91,342	3,81,77,479	
3	Plant & Machinery	16,02,69,989	1,82,30,964	-	-	8,26,03,406	8,09,45,313	
4	Laboratory Equipment	6,74,000	86,144	-	-	3,47,612	3,10,437	
5	Electric Installation	59,51,390	13,39,161	-	-	28,61,109	36,68,385	
6	Furniture & Fixtures	7,42,640	24,58,739	-	-	6,55,741	29,38,541	
7	Office Equipments	15,96,723	9,60,365	-	-	9,78,746	15,87,468	
8	Computer and Printers	7,43,251	2,49,772	-	-	1,14,397	2,69,966	
9	Vehicles	27,84,890	-	-	-	18,95,157	15,65,895	
		21,59,43,746	2,82,21,299	-	-	12,60,47,510	13,14,63,484	
	Intangible Assets							
1	Software	4,50,000	-	-	-	4,43,519	3,58,019	
		4,50,000	-	-	-	4,43,519	3,58,019	
	Capital work in progress	2,31,60,048	1,42,53,630	1,96,21,625	-	2,31,60,048	1,77,92,053	
	Total	23,95,53,794	4,24,74,929	1,96,21,625	-	14,96,51,077	14,96,13,556	
	Previous Year Figures	22,70,25,842	1,50,27,952	25,00,000	-	16,06,29,075	14,96,51,077	



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

10. Long Term Loans and Advances

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Misc. Expenditure to the extent not W/off		12,66,700		18,81,300
Balance with Government Authorities		-		25,61,712
Advance to Suppliers for Capital Goods		23,05,000		15,79,164
Security Deposits				
Unsecured, considered good		21,79,459		31,73,820
Doubtful				
Total		57,51,159		91,95,996

11. Current Investments

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Investments in Mutual Funds				
- SBI Liquid Fund Regular Growth		80,81,731		1,94,94,876
- Investment in 8.85% HDFC Bank Perpetual		2,28,59,700		
Total		3,09,41,431		1,94,94,876

12. Inventories

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Raw Material		3,35,38,136		2,56,06,260
Finished Goods		3,09,24,828		1,99,75,983
Work in progress		-		1,99,943
Stores and Spares		94,026		90,320
Packing Material		1,21,665		2,22,150
Total		6,46,78,655		4,60,94,656

13. Trade Receivables

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Debt outstanding for a period exceeding six months				
Unsecure considered good		3,62,404		41,17,076
Doubtful		-		-
Debt outstanding for a period not exceeding six months				
Unsecure considered good		6,47,89,156		7,50,37,035
Doubtful		-		-
(a) Debt due by Directors		-		-
(b) Debt due by Relatives of Directors		-		-
(c) Debt due by Firm or Companies in which Directors are interested		-		-
Total		6,51,51,560		7,91,54,111



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

14. Cash and cash Equivalents

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Cash on hand		11,96,634		12,79,005
Balances with banks - In Current Accounts		36,19,204		3,11,00,612
Balances with banks - In Fixed Deposits		49,69,052		41,00,000
Total		97,84,890		3,64,79,617

15. Short Term Loans and Advances

Particulars	As at 31 March, 2020		As at 31 March, 2019	
Balance with Government Authorities		76,36,879		2,92,41,581
Advance to Staff		4,25,063		6,13,384
Advance to Suppliers		1,42,196		-
Other Loans and Advances		21,23,937		15,68,842
Total		1,03,28,075		3,14,23,807



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

16. Revenue from operations

Particulars	2019-20	2018-19
Sales of Products		
(a) Domestic Sales		
(i) By way of Manufacturing	22,05,85,559	20,98,89,314
(ii) By way of Trading	1,64,54,077	-
(b) Export Sales		
(i) By way of Manufacturing	21,13,84,032	30,39,95,571
(ii) By way of Trading	-	2,56,50,156
Other Operating Income	57,63,386	94,83,807
Total	45,41,87,054	54,90,18,848

17. Other Income

Particulars	2019-20	2018-19
Interest Income	13,97,940	26,26,415
Profit on sale of Liquid Funds	20,58,757	9,13,083
Miscellaneous Income	3,985	-
Total	34,60,682	35,39,498

18. Cost of Material Consumed

Particulars	2019-20	2018-19
Opening stock	2,56,06,260	5,04,75,424
Add : Purchases	31,03,27,785	35,70,28,199
Closing Stock	3,35,38,136	2,56,06,260
Total	30,23,95,909	38,18,97,363

19. Increase / decrease in inventories

Particulars	2019-20	2018-19
<u>Inventories at the end of the year</u>		
Closing stock of finished goods	3,09,24,828	1,99,75,983
Closing stock of work in progress	-	1,99,943
	3,09,24,828	2,01,75,926
<u>Inventories at the beginning of the year</u>		
Opening stock of finished goods	1,99,75,983	2,49,24,170
Opening stock of work in progress	1,99,943	55,67,500
	2,01,75,926	3,04,91,670
Net Increase /(decrease)	(1,07,48,902)	1,03,15,744



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

20. Employee Benefits Expense

Particulars	2019-20	2018-19
Director Remuneration	24,78,162	24,78,160
Salaries and Wages	4,40,12,624	2,37,44,174
Contribution to Provident Fund and Other Funds	6,81,946	6,11,049
Staff Welfare Exps.	7,75,660	5,37,516
Total	4,79,48,392	2,73,70,899

21. Financial Expenses

Particulars	2019-20	2018-19
Interest Expenses		
- paid for Short Term Borrowings	14,67,012	36,19,761
- paid for Term Loans	37,97,177	44,99,358
- paid for Unsecured loans	34,65,354	59,11,648
- paid for Others	1,77,776	3,56,531
Bank charges	9,70,421	19,50,193
Total	98,77,740	1,63,37,490

22. Administrative Expenses

Particulars	2019-20	2018-19
Annual Fees	12,141	43,828
Books & Periodicals	2,030	4,050
Communication Expenses	3,49,812	3,20,987
Donation Exp.	-	1,200
Audit Fees	30,000	30,000
Pest Control Services	-	-
Listing Related Expenses	1,01,960	1,83,949
Insurance Exp.	8,17,639	6,84,958
Professional & Consulting Fees	13,42,975	16,03,800
Membership Fees	8,49,694	6,35,928
Office & General Exp.	4,33,104	3,80,540
Petrol & Conveyence Exp	2,65,496	3,91,941
Postage & Courier Exp	1,62,247	1,90,443
Printing & Stationary Expenses [Bvn]	1,03,730	2,20,766
Rent Rates & Taxes	3,36,785	3,92,143
Vehicle Repairing Exp [Bvn]	48,912	26,839
Sundry Amount Written Off	4,31,820	48,814
Security Exps	12,63,448	9,56,390
Preliminary Expenses written off	6,14,600	6,14,600
Miscellaneous Expensese	16,26,867	7,39,126
Total	87,93,260	74,70,302



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
NOTES TO ACCOUNTS AS ON 31ST MARCH, 2020

23. Manufacturing Expenses

Particulars	2019-20	2018-19
Stores & Consumables	1,09,97,728	1,16,98,938
Power and Fuel	1,49,72,142	1,53,91,292
Job Work Charges	15,91,050	72,31,500
Freight & Transport Charges	24,23,440	42,01,030
Other Manufacturings Exps.	21,74,224	13,08,762
Total	3,21,58,584	3,98,31,522

24. Selling and Distribution Expenses

Particulars	2019-20	2018-19
Advertisement Exp	-	-
Travelling Expense Foreign	4,04,017	7,74,104
Travelling Expense. Local	6,76,753	3,75,203
Business Promotion Expenses	1,57,507	-
ECGC Premium	1,41,750	-
Export Related Expenses	74,19,344	1,20,62,395
Export Sales Commission	46,26,672	71,76,244
Total	1,34,26,043	2,03,87,946



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

CORPORATE INFORMATION:

Arvee Laboratories (India) Ltd. ("the company") is a listed entity on incorporated in India. The Shares of the company are listed on the NSE SME Board.

The addresses of its registered office is 403, ENTICE Building, Opposite Jayantilal Park BRTS Bus Stop, Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

The plant of the company is situated at Survey No. 316, Bhavnagar Sihor Road, Post: Vartej, Kardej, Dist. Bhavnagar, PIN-364060, Gujarat, India. The company is engaged in manufacturing of specialized chemicals.

1.0. SIGNIFICANT ACCOUNTING POLICIES:

The significant accounting policies applied by the Company in the preparation of its financial statements are listed below. Such accounting policies have been applied consistently to all the periods presented in these financial statements unless otherwise indicated.

1.1 Basis of preparation of accounts:

The financial statements are prepared under the historical cost convention on the "Accrual Concept" of accountancy in accordance with the accounting principles generally accepted in India and comply with the accounting standards issued by the Institute of Chartered Accountants of India to the extent applicable and with the relevant provisions of the Companies Act, 2013.

1.2 Use of Estimates:

The preparation of the financial statements requires estimates and assumption to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual result and estimates are recognized in the period in which the results are known / materialized.


1.3 Current & Non-current Classification:

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle (twelve months) and other criteria set out in Schedule III to the Act.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. Based on the nature of business and its activities, the Company has ascertained its operating cycle as twelve months for the purpose of Current & Non-Current classification of assets and liabilities.

1.4 Tangible Assets:

Tangible Assets are stated at cost of acquisition and subsequent improvements net of CENVAT credit and VAT but including freight and other incidental expenses related to acquisition, installation and foundation less accumulated depreciation and any other financial assistance received from government or any other party in the form of capital receipt . All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the Tangible Assets are capitalized.



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

1.5 Intangible Assets:

Intangible Assets are stated at cost, of acquisition net of recoverable taxes, trade discount and rebates less accumulated amortization / depletion and impairment losses, if any. Such cost includes purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the Intangible Assets.

Amortization policies applied to the Company's Intangible Assets to the extent of depreciable amount is as follows:

Particular	Depreciation
Computer Software	over a period of 5 years

1.6 Capital Work in Progress and Capital advances:

Cost of assets not ready for intended use, as on the balance sheet date, is shown as capital work in progress. Advances given towards acquisition of fixed assets outstanding at each balance sheet date are disclosed as Other Non-current Assets.

1.7 Depreciation Accounting:

Depreciation has been provided on straight line method (SLM) over the useful life of the Tangible Assets as defined in the Schedule II of the Companies Act, 2013. The life has been decided by the management considering the type and nature of the assets as defined in the Schedule II of the Companies Act, 2013.

1.8 Loans and Borrowings :

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the Effective Interest Rate (EIR) method. Gains and losses are recognised in Statement of profit or loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of Profit and Loss. Borrowing costs attributable to acquisition or construction of a qualifying asset are capitalized as part of cost of that asset. Other borrowing costs are recognized as expense in the period in which these are incurred.

1.9 Investments :

Investments in mutual funds are classified as Current Investments. Current Investments are valued at lower of cost or fair value.

1.10 Inventory :

Items of inventories are measured at lower of cost and net realizable value after providing for obsolescence, if any, except in case of by-products which are valued at net realizable value. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads net of recoverable taxes incurred in bringing them to their respective present location and condition.

Cost of raw materials, chemicals, stores and spares, packing materials, trading and other products are determined on weighted average basis.

1.11 Impairment of Assets:



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

An assets is treated as impaired when the carrying cost of assets exceeds its recoverable value and impairment loss is charged to profit and loss account in the period in which assets is identified as impaired. The impairment loss, if any recognized in prior accounting periods is reversed if there has been a changed in the estimate of recoverable amount.

1.12 Borrowing Cost:

All borrowing costs are recognized as expenses in the period in which they are incurred, except to the extent where borrowing costs that are directly attributable to the acquisition, construction or production of an asset till ready for intended use is capitalized as a part of the cost of that asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs (except as stated in notes) is charged to revenue.

1.13 Deferred Revenue Expenditure

Expenditure relating to Preliminary expenses, capital issue and deferred revenue expense is amortized on straight line basis over a period of 5 years.

1.14 Revenue Recognition:

Sales

Sales are recognized when goods are supplied and are recorded net of trade discounts, rebates and duties and taxes, but includes export incentives.

Interest

Revenue is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

Export Incentive

MEIS receivable on Export of Goods is recognized on the basis of claim disbursement by the relevant authority.


1.15 Accounting for Taxes on Income:

Current tax is determined as the amount of tax payable in respect of taxable income for the period and the credits computed in accordance with the provisions of the Income Tax Act, 1961.

Deferred tax resulting from "timing difference" between taxable incomes and accounting income is accounted for, using the tax rates and tax laws that have been enacted or substantially enacted as on the Balance Sheet date.

1.16 Provisions, Contingent Liabilities and Contingent Assets :

Provisions are recognized when the present obligations of a past event gives rise to a probable outflow, embodying economic benefits on settlement and the amount of obligation can be reliably estimated. Contingent Liabilities being a possible obligation as a result of past events the existence of which will be confirmed by the occurrence or non-occurrence of one or more future events not wholly in the control of the company. Contingent Liabilities are not recognized in the accounts. Further the nature of such liabilities, an estimate of its financial effect, etc. is disclosed as a part of Notes to Accounts.



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

1.17 Lease Rentals:

Operating lease is charged to profit and loss account on accrual basis.

1.18 Foreign exchange transactions:

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognized in Statement of Profit and Loss except to the extent of exchange differences which are regarded as an adjustment to interest costs on foreign currency borrowings that are directly attributable to the acquisition or construction of qualifying assets, are capitalized as cost of assets.

1.19 Employee Benefits:

Contributions to defined contribution schemes such as employees' provident fund and family pension fund are charged to the statement of profit and loss account as and when incurred.

Leave encashment / Gratuity a liability of the company is provided on the basis of actuarial valuation.

1.20 Segment Reporting:

The company has only one geographical segment and one business segment. Therefore, Reporting under AS-17 is not required to be disclosed.

1.21 Finance Cost :

Finance Cost includes interest, bank charges incurred in connection with the arrangements of borrowing. Finance costs that are directly attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets.

1.22 Cash and Cash Equivalent:

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of twelve months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, as they are considered an integral part of the Company's cash management.

1.23 Earnings per Share:

Basic earnings per share are calculated by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

1.24 General:

Accounting policies not specially referred to are consistent with generally accepted accounting policies.



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

2.0. NOTES TO ACCOUNTS:

25. Figures of previous year are regrouped and rearranged whenever necessary and rounded off to the nearest rupee for better presentation of accounts. The notes referred in the balance sheet and profit and loss statement form an integral part of the accounts. The Debit and Credit balances of debtors, creditors, loans and advances and unsecured loans are subject to confirmation and reconciliation.
26. In the opinion of the Directors, and to the best of their knowledge and belief, the value of realization of current assets and loans and advances in the ordinary course of business would not be less than the amount at which they are stated in the balance sheet. Provision for all known liabilities is adequate and not in excess of amount reasonably necessary.
27. Considering the nature of Company's business and operation, there are no separate reportable segments (business or geographical) in accordance with the requirements of Accounting Standard 17 – "Segmental Reporting".

28. Audit Fees

Sr. No	Particulars	(Amount in Rs.)	
		2019-20	2018-19
1	Audit Fees	30,000/-	30,000/-
2	Taxation Matters	-	-

29. Related Party Disclosure – AS 18

a. Related Parties and their relationship

Name of the related party	Relationship
Mr. Shalin Patel	Key Managerial Personnel
Mr. Shalin Chokshi	Key Managerial Personnel
Mr. Vishal Nitin Mehta	Director
Mrs. Chandrakala Ashok Bhatt	Director
Mr. Sudhakar Patel	Director's Father
Mrs. Forum S Chokshi	Director's Relative
Mrs. Kavita S Chokshi	Director's Wife
Mrs. Khusboo S Patel	Director's Wife
Mr. Bharatbhai R Chokshi	Director's Father
Mr. Shalin Chokshi HUF	Director's HUF
Mr. Shalin Patel HUF	Director's HUF
Mr. Saumil Chokshi HUF	Director's Brother's HUF
Mr. Sudhakar C Patel HUF	Director's Father's HUF
Mrs. Chandrabalaben S Patel	Director's Mother
B Chokshi Chem Pvt. Ltd.	Associate Concern



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
Financial Year: 2019-20

b. Transactions with Related Parties

Sr. No.	Name of Related Party	Interest paid		Remuneration		Loan Taken		Loan Repaid		Closing Balance	
		2019-20	2018-19	2019-20	2018-19	2019-20	2018-19	2019-20	2018-19	2019-20	2018-19
Key Managerial Personnel:											
1.	Mr. Shalin Patel	-	151622	1239081	1239080	-	-	-	23059239	-	-
2.	Mr. Shalin Chokshi	215825	-	1239081	1239080	9750000	-	9965825	-	-	-
Relatives of Key managerial Personnel:											
3.	Mr Sudhakar Patel	-	337507	-	-	-	670817	-	3000000	-	-
4.	Ms Khusboo Patel	934273	1088460	-	-	-	-	-	13911578	6200000	6200000
5.	Ms Forum Chokshi	491829	468078	-	-	3300000	11250000	3791829	11368467	-	-
6.	Ms Kavita Chokshi	28517	461005	-	-	240788	11250000	269305	11368466	-	-
7.	Mr Bharatbhai Chokshi	-	489271	-	-	-	7000000	-	7000000	-	-
8.	Mr. Shalin Patel HUF	429464	460993	-	-	-	4000000	-	1150000	2850000	2850000
9.	Mr. Shalin Chokshi HUF	296984	686302	-	-	10000000	5000000	10296984	5000000	-	-
10.	Mr Saumil Chokshi HUF	736946	686301	-	-	10000000	5000000	10736946	5000000	-	-
11.	Mr Sudhakar Patel HUF	331516	502253	-	-	-	4000000	-	1800000	2200000	2200000
12.	Mrs Chandrabala Patel	-	564288	-	-	-	4500000	-	4500000	-	-



Arvee Laboratories (India) Ltd.
CIN: L24231GJ2012PLC068778
Financial Year: 2019-20

Associate Concern:

Nature of Transactions	2019-20	2018-19
Purchase of Goods		
B. Chokshi Chem Pvt Ltd	5797242	32838116
Sale of Goods		
B. Chokshi Chem Pvt Ltd	1851090	-
Closing Balance		
B. Chokshi Chem Pvt Ltd	-	1161655

30. In compliance of AS-20 on Earning per share, issued by the ICAI, the elements considered for calculation of earnings per share (Basic and Diluted as under:

Particulars	Current year Amount	Previous year Amount
Net profit/(Loss) after tax available for the equity share holders	22,269,758	22,628,839
Weighted average number of equity shares	5,510,000	5,510,000
Nominal/Face value of equity shares (Rupees)	10	10
Basic and Diluted earnings per share	4.04	4.11

31. Taxation :

32.1 Deferred Tax Liabilities:

Particulars of Deferred Tax	2019-20		2018-19	
	Asset	Liability	Asset	Liability
Opening Balance	-	5,788,112	-	8,620,064
WDV as per Companies Act, 2013	-	129,821,503	-	124,491,029
WDV as per Income Tax, 1961	-	114,061,206	-	103,685,452
Diff. in WDV due to timing difference	-	15,760,297	-	20,805,577
Deferred tax liability for the year – Balance Sheet Item	-	4,384,515	-	5,788,112
Net Deferred Tax Exps /(Income) – Profit & Loss Item	-	(1,403,597)	-	(2,831,952)
Opening Balance	129,021		1,301,402	-
Net Disallowance of Provision for Gratuity	601,270		463,770	-
Deferred tax Asset – Balance Sheet Item	167,273		129,021	-
Net Deferred Tax Exps / (Income) – Profit & Loss Item	(38,252)		1,172,381	-
Net Deferred Tax Exps / (Income) recognized in Profit & Loss		(1,441,850)	-	(1,659,571)
Net Deferred Tax liability (Asset) reflected in Balance Sheet		4,217,241	-	5,659,091



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

31.2 Current Tax :

Particulars of Current Tax	2019-20	2018-19
Profit Before Tax	30,905,885	25,441,129
Add : Expenses to the extent disallowable	23,165,311	24,737,051
Less : Expenses to the extent Allowable	17,845,544	16,414,880
Less: Adjustment of Brought Forward Loss	-	4,211,660
Net Taxable Profit	36,225,652	29,551,640
Current Tax @27.82%	10,077,976	8,221,266
Less : MAT Credit Entitlement	-	3,906,211
Net Current Tax recognized in P&L Account	10,077,976	4,315,055

32. Other Information:

a) CIF value of Imports:

Particulars	2019-20	2018-19
Raw Material	167,391,908	181,597,622

b) Particulars of Expenditure in Foreign Exchange:

Particulars	2019-20	2018-19
Export sales commission	2,552,922	7,116,244
Travelling Expense	155,201	70,000

c) Particulars of Earnings in Foreign Exchange:

Particulars	2019-20	2018-19
Export of goods/Services on FOB basis	200,621,233	312,822,289
C & F Charges	10,194,141	16,823,438

d) Consumption of Material:

Particulars	2019-20		2018-19	
	Amount Rs.	%	Amount Rs.	Amount Rs.
Raw Material				
- Indigenous	129,984,983	42.99%	188,879,116	49.46%
- Imported	172,410,926	57.01%	193,018,246	50.54%
Total	302,395,909	100.00%	381,897,362	100.00%

e) Unhedged Foreign Currency Exposure:

Particulars	Currency	2019-20	2018-19
Receivable	USD	75,992.50	163,630.00
Payable	USD	0.00	356,940.00
Receivable	EURO	527,676.50	240,200.00
Payable	EURO	0.00	10,052.00



Arvee Laboratories (India) Ltd.

CIN: L24231GJ2012PLC068778

Financial Year: 2019-20

33. Contingent liabilities and commitments

Contingent liabilities and commitments (to the extent not provided for)	AS AT 31.3.2020	AS AT 31.3.2019
(i) Contingent Liabilities		
(a) Claims against the company not acknowledged as debt	32560	32560
(b) Guarantees	Nil	50000
(c) Other money for which the company is contingently liable	Nil	Nil
(ii) Commitments		
(a) Estimated amount of contracts remaining to be executed on capital account and not provided for	Nil	Nil
(b) Uncalled liability on shares and other investments partly paid	Nil	Nil
(c) Other commitments (specify nature) (LC discounted)	Nil	5154240

34. Other disclosure required under schedule – III of Companies Act, 2013 are either Nil or Not Applicable.

As per our separate report
of even date attached herewith

For K C J M & Associates
Chartered Accountants

Kabir Mansuri
(Partner)

Membership No. : 126585

Firm Registration no :- 121324W



Place : Ahmedabad

Date : 29/06/2020

UDIN : 20126585AAAABC6378

For Arvee Laboratories (India) Ltd.

Shalin Patel

Director

DIN: 01779902

Saurin A Gandhi


Chief Financial Officer

PAN: AJUPG7995F

Shalin Chokshi

Director

DIN: 00191903



Raina Singh Chauhan

Company Secretary

M. No. 57624